homovanillic acid has been researched along with Parkinson Disease in 333 studies
Homovanillic Acid: A 3-O-methyl ETHER of (3,4-dihydroxyphenyl)acetic acid.
homovanillate : A hydroxy monocarboxylic acid anion which is obtained by deprotonation of the carboxy group of homovanillic acid.
homovanillic acid : A monocarboxylic acid that is the 3-O-methyl ether of (3,4-dihydroxyphenyl)acetic acid. It is a catecholamine metabolite.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The relationships between magnitude of response to orally administered carbidopa/levodopa (CD/LD) and serum/cerebrospinal fluid (CSF) concentrations of levodopa (LD), 3-O-methyldopa (3-O-MD), and homovanillic acid (HVA) were studied in 15 patients with chronic LD-treated Parkinson disease." | 7.67 | Magnitude of response to levodopa in Parkinson disease as it relates to peripheral and central measurements of levodopa and associated metabolites. ( Davoudi, H; Durso, R; Feldman, RG; Szabo, G, 1989) |
| "Exposure to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) produces a syndrome that resembles Parkinson's disease." | 7.67 | The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). ( Burns, RS; Ebert, MH; Kopin, IJ; LeWitt, PA; Pakkenberg, H, 1985) |
| "Ventricular fluid concentrations of homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5-HIAA), the respective metabolites of dopamine and serotonin, were measured in 57 patients undergoing thalamotomy for relief of movement disorders." | 7.66 | Ventricular fluid homovanillic acid and 5-hydroxyindoleacetic acid concentrations in patients with movement disorders. ( Sharpless, NS; Tabaddor, K; Wolfson, LI, 1978) |
| "In the murine model of early Parkinson's disease, the balance between dopamine and 5-hydroxytryptamine systems varied among brain regions." | 5.91 | Serotonin and dopamine depletion in distinct brain regions may cause anxiety in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice as a model of early Parkinson's disease. ( He, L; Huang, H; Shi, J; Xie, S; Yang, R; Yang, Y; Ye, S; Zhang, S; Zhang, Y, 2023) |
| "Rapid-onset dystonia-parkinsonism (RDP) is characterized by sudden onset over hours to days of dystonia, dysphagia, dysarthria, and parkinsonism." | 5.30 | Cerebrospinal fluid homovanillic acid levels in rapid-onset dystonia-parkinsonism. ( Brashear, A; Butler, IJ; Dobyns, WB; Farlow, MR; Hyland, K, 1998) |
| "In the patient group with visual hallucinations, mean salsolinol level was significantly increased to almost the 3-fold of those found in patients without hallucinations." | 5.29 | Salsolinol, catecholamine metabolites, and visual hallucinations in L-dopa treated patients with Parkinson's disease. ( Jaskowski, P; Kömpf, D; Moser, A; Siebecker, F; Vieregge, P, 1996) |
| "A paucity of information is available concerning the use of levodopa and carbidopa during pregnancy." | 5.08 | Human transplacental transfer of carbidopa/levodopa. ( Cohen, G; DiRocco, A; Merchant, CA; Molinari, S; Moros, D; Mytilineou, C; Yahr, MD, 1995) |
| "Rapid-onset dystonia-parkinsonism (RDP) is a genetic movement disorder characterized by abrupt onset over hours to days of bradykinesia, postural instability, dysphagia, dysarthria, and severe dystonic spasms with decreased levels of the dopamine metabolite, homovanillic acid (HVA), in cerebrospinal fluid (CSF)." | 3.70 | PET imaging of the pre-synaptic dopamine uptake sites in rapid-onset dystonia-parkinsonism (RDP). ( Brashear, A; Farlow, MR; Hutchins, GD; Mulholland, GK; Siemers, ER; Zheng, QH, 1999) |
| "We report a family with autosomal dominant type hereditary juvenile dystonia-parkinsonism in which eight members in three generations exhibited parkinsonism, sleep benefit, marked efficacy of levodopa, wearing-off phenomenon, and dopa-induced choreic dyskinesia." | 3.69 | A family with hereditary juvenile dystonia-parkinsonism. ( Ishikawa, A; Miyatake, T, 1995) |
| "We investigated the effect of GM1 gangliosides on a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) animal model of Parkinson disease." | 3.68 | GM1 gangliosides alter acute MPTP-induced behavioral and neurochemical toxicity in mice. ( Albert, ML; Davoudi, H; Durso, R; Fazzini, E; Szabo, GK, 1990) |
| "The long-term effect of the parkinsonism-inducing neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central monoaminergic neurons in young (2-3 months) and aging (12 months) C57BL/6 mice has been studied using neurochemical and immunocytochemical techniques." | 3.68 | Long-term effect of MPTP in the mouse brain in relation to aging: neurochemical and immunocytochemical analysis. ( Date, I; Felten, DL; Felten, SY, 1990) |
| "To examine the possible causal contribution of normal or accelerated aging to the neurodegenerative process of Parkinson's disease, we measured the influence of aging on subregional striatal dopamine and homovanillic acid levels in postmortem brain of 23 neurologically and psychiatrically normal human subjects 14-92 years old." | 3.68 | Aging produces a specific pattern of striatal dopamine loss: implications for the etiology of idiopathic Parkinson's disease. ( Deck, JH; Hornykiewicz, O; Kish, SJ; Rajput, A; Shannak, K, 1992) |
| "In four human controls, four cases of Parkinson's disease and three cases of amyotrophic lateral sclerosis analysis of dopamine, noradrenaline, serotonin and the metabolites 3,4-dihydroxyphenylacetic acid, homovanillic acid and 5-hydroxyindoleacetic acid was performed in various segments of postmortem spinal cord." | 3.68 | Biogenic amines and metabolites in spinal cord of patients with Parkinson's disease and amyotrophic lateral sclerosis. ( Gavranovic, M; Gsell, W; Jellinger, K; Riederer, P; Schmidtke, A; Sofic, E, 1991) |
| "A distinct pattern of neuropsychological deficits was associated with low homovanillic acid (HVA) in the cerebrospinal fluid of 21 patients with: Alzheimer's disease (9), Parkinson's disease (8) and major depressive disorders (4)." | 3.68 | Neuropsychological profile linked to low dopamine: in Alzheimer's disease, major depression, and Parkinson's disease. ( Albert, ML; Almozlino, A; Durso, R; Katz, DI; Smith, MC; Volicer, L; Wolfe, N, 1990) |
| " We tested patients with PD, patients with Alzheimer's type of senile dementia, and a control group neuropsychologically, and we determined their CSF levels of homovanillic acid, 3,4-dihydroxyphenylacetic acid, 3-methoxy-4-hydroxyphenylglycol, 5-hydroxyindolacetic acid, serotonin, and acetylcholinesterase." | 3.67 | Parkinson's disease. The possible relationship of laterality to dementia and neurochemical findings. ( Albert, ML; Direnfeld, LK; Kaplan, E; Langlais, PJ; Marquis, J; Volicer, L, 1984) |
| "Mean levels of the two hydrolases angiotensin-converting enzyme (ACE) and acetylcholinesterase (AChE), the dopamine metabolites dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA), and total protein concentration were examined in cerebrospinal fluid (CSF) samples from a group of patients with dementia of the Alzheimer's type, a group of comparably demented patients with Parkinson's disease, and a neurologically healthy elderly control group." | 3.67 | Cerebrospinal fluid levels of angiotensin-converting enzyme, acetylcholinesterase, and dopamine metabolites in dementia associated with Alzheimer's disease and Parkinson's disease: a correlative study. ( Direnfeld, LK; Langlais, PJ; Marquis, JK; Nixon, RA; Volicer, L; Zubenko, GS, 1986) |
| "The relationships between magnitude of response to orally administered carbidopa/levodopa (CD/LD) and serum/cerebrospinal fluid (CSF) concentrations of levodopa (LD), 3-O-methyldopa (3-O-MD), and homovanillic acid (HVA) were studied in 15 patients with chronic LD-treated Parkinson disease." | 3.67 | Magnitude of response to levodopa in Parkinson disease as it relates to peripheral and central measurements of levodopa and associated metabolites. ( Davoudi, H; Durso, R; Feldman, RG; Szabo, G, 1989) |
| "Exposure to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) produces a syndrome that resembles Parkinson's disease." | 3.67 | The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). ( Burns, RS; Ebert, MH; Kopin, IJ; LeWitt, PA; Pakkenberg, H, 1985) |
| "The relationship between dopamine receptor stimulation by bromocriptine or levodopa and the relief of parkinsonism was studied in 24 patients with Parkinson disease." | 3.66 | Brain dopamine receptor stimulation and the relief of Parkinsonism: relationship between bromocriptine and levodopa. ( Marttila, R; Rinne, UK, 1978) |
| "Ventricular fluid concentrations of homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5-HIAA), the respective metabolites of dopamine and serotonin, were measured in 57 patients undergoing thalamotomy for relief of movement disorders." | 3.66 | Ventricular fluid homovanillic acid and 5-hydroxyindoleacetic acid concentrations in patients with movement disorders. ( Sharpless, NS; Tabaddor, K; Wolfson, LI, 1978) |
| "Probenecid was administered to 7 unipolar depressed patients, 7 parkinsonians and 7 extrapyramidal patients with senile dementia matched for age and sex." | 3.66 | Biogenic amine disturbances in cerebrospinal fluid in parkinsonism and unipolar depression: use of the probenecid method. ( Mendlewicz, J; Noel, G; Vanderheyden, JE, 1981) |
| "The probenecid technique was used in study of the central dopamine DA metabolism in patients with depressions, psychotic disorders, and Parkinson's disease." | 3.65 | Dopamine metabolism in depressions, psychoses, and Parkinson's disease: the problem of the specificity of biological variables in behaviour disorders. ( Korf, J; Praag, HM; Schut, T, 1975) |
| "We have studied the urinary excretion of 1,4-methylhistamine (1,4-MeHm), 5-hydroxyindole-3-acetic acid (5-HIAA) and homovanillic acid (HVA) in patients with Parkinson's disease, choreiform movements and essential tremor." | 3.65 | Urinary monoamine metabolite excretion in disorders of movement. Effects of amantadine and levodopa. ( Fleming, AM; Lenman, JA; Reid, A; Turnbull, MJ, 1977) |
| "Thus entacapone seems to be a valuable adjuvant to levodopa treatment in parkinsonian patients with end-of-dose failure." | 2.68 | Effect of one month's treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients. ( Rinne, UK; Ruottinen, HM, 1996) |
| " Entacapone significantly increased the mean area under the plasma concentration curve (AUC) of levodopa by 46%, from 3620 to 5280 h." | 2.67 | Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease. ( Illi, A; Keränen, T; Myllylä, VV; Sotaniemi, KA; Suominen, K, 1993) |
| "Parkinson's disease is characterized by the loss of midbrain dopamine neurons that innervate the caudate and the putamen." | 2.67 | Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with Parkinson's disease. ( Bunney, BS; Gjedde, A; Leranth, C; Marek, KL; Naftolin, F; Price, LH; Robbins, RJ; Roth, RH; Spencer, DD; Vollmer, T, 1992) |
| " The results suggest, the BH4 in the dosage used, is not effective in the treatment of Parkinson's disease." | 2.66 | Tetrahydrobiopterin and Parkinson's disease. ( Dissing, IC; Gerdes, AM; Güttler, F; Lou, H; Lykkelund, C; Pakkenberg, H; Rasmussen, V, 1989) |
| "Eleven patients with severe Parkinson's disease and on-off-phenomena were included in a controlled double-blind study on the effect of electroconvulsive therapy (ECT)." | 2.66 | A double-blind evaluation of electroconvulsive therapy in Parkinson's disease with "on-off" phenomena. ( Andersen, K; Balldin, J; Gottfries, CG; Granérus, AK; Modigh, K; Svennerholm, L; Wallin, A, 1987) |
| "It is controversial if early onset Parkinson's disease (EOPD) (onset at < 41 years of age) is Parkinson's disease (PD) occurring at a younger age or a different disease." | 2.39 | Early onset Parkinson's disease: are juvenile- and young-onset different? ( Muthane, UB; Rao, S; Satishchandra, P; Subbakrishna, D; Subhash, MN; Swamy, HS, 1994) |
| "Presymptomatic detection of Parkinson's disease is necessary if neuroprotective therapies are to be utilized in its treatment." | 2.38 | Presymptomatic detection of Parkinson's disease. ( Jenner, P, 1993) |
| "With the exception of Parkinson's disease, there is little evidence that treatments which decrease DA function are potent inducers of depression, but it is argued that such a relationship might not necessarily be expected." | 2.36 | Dopamine and depression: a review of recent evidence. I. Empirical studies. ( Willner, P, 1983) |
| " This review summarises that available pharmacokinetic data involving levodopa, especially as it relates to therapeutic response of parkinsonian patients." | 2.35 | Clinical pharmacokinetics of levodopa in parkinson's disease. ( Bianchine, JR; Shaw, GM, 1976) |
| "In the murine model of early Parkinson's disease, the balance between dopamine and 5-hydroxytryptamine systems varied among brain regions." | 1.91 | Serotonin and dopamine depletion in distinct brain regions may cause anxiety in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice as a model of early Parkinson's disease. ( He, L; Huang, H; Shi, J; Xie, S; Yang, R; Yang, Y; Ye, S; Zhang, S; Zhang, Y, 2023) |
| "The three synucleinopathies therefore have in common in vivo evidence of central noradrenergic deficiency but differ in the extents of central dopaminergic deficiency-prominent in PD and MSA, less apparent in PAF." | 1.62 | Differential abnormalities of cerebrospinal fluid dopaminergic versus noradrenergic indices in synucleinopathies. ( Goldstein, DS; Holmes, C; Lamotte, G; Lenka, A; Sharabi, Y; Sullivan, P, 2021) |
| "Lewy body disorders, including Parkinson's disease (PD), Parkinson's disease dementia (PDD) and dementia with Lewy bodies (DLB), are characterized by profound central and peripheral monoaminergic dysfunction." | 1.48 | Monoaminergic Markers Across the Cognitive Spectrum of Lewy Body Disease. ( Aerts, T; De Deyn, PP; Fransen, E; Gerritsen, MJ; Spikman, JM; Van Dam, D; van der Zee, S; van Laar, T; Vermeiren, Y, 2018) |
| "In a model of early-stage Parkinson's disease induced by a single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to Wistar rats, a neuroprotective effect of a new derivative of carnosine and α-lipoic acid (C/LA nanomicellar complex) was demonstrated." | 1.48 | Neuroprotective effect of the carnosine - α-lipoic acid nanomicellar complex in a model of early-stage Parkinson's disease. ( Berezhnoy, DS; Fedorova, TN; Kulikova, OI; Lopachev, AV; Orlova, VS; Stvolinsky, SL, 2018) |
| "In the BACHD model of Huntington's disease we demonstrate that the vector can be kept in a continuous ON-state for extended periods of time." | 1.48 | Therapeutic efficacy of regulable GDNF expression for Huntington's and Parkinson's disease by a high-induction, background-free "GeneSwitch" vector. ( Bähr, M; Cheng, S; Déglon, N; Konstantinova, P; Kügler, S; Liefhebber, J; Mazur, A; Pythoud, C; Raina, A; Rey, M; Streit, F; Tereshchenko, J; Vachey, G; Zimmer, V, 2018) |
| "Zonisamide (ZNS) is an effective drug for not only motor symptoms but also non-motor symptoms in Parkinson's disease." | 1.46 | Zonisamide inhibits monoamine oxidase and enhances motor performance and social activity. ( Asano, T; Hikawa, R; Takahashi, R; Uemura, MT; Yamakado, H, 2017) |
| "Levodopa (l-DOPA, l-3,4-dihydroxyphenylalanine) is the most effective drug in the symptomatic treatment of Parkinson's disease (PD), but chronic use initiates a maladaptive process leading to l-DOPA-induced dyskinesia (LID)." | 1.46 | Cerebrospinal fluid levels of catecholamines and its metabolites in Parkinson's disease: effect of l-DOPA treatment and changes in levodopa-induced dyskinesia. ( Andersen, AD; Binzer, M; Blaabjerg, M; Gramsbergen, JBP; Kamal, A; Kjaer, TW; Stenager, E; Thagesen, H, 2017) |
| "Current research on Parkinson's disease (PD) pathogenesis requires relevant animal models that mimic the gradual and progressive development of neuronal dysfunction and degeneration that characterizes the disease." | 1.42 | Progressive nigrostriatal terminal dysfunction and degeneration in the engrailed1 heterozygous mouse model of Parkinson's disease. ( Beauvais, G; Brundin, P; Escobar Galvis, ML; Feinstein, TN; Fuchs, J; Ghosh, A; Joshi, RL; Lipton, JW; Lundblad, M; Medicetty, S; Nordströma, U; Prochiantz, A; Pulikkaparambil Sasidharan, BC; Roholt, A; Steiner, JA, 2015) |
| "Lactacystin is a selective UPS inhibitor recently used to destroy dopamine (DA) neurons in animal models of Parkinson's disease (PD)." | 1.42 | Decreased behavioral response to intranigrally administered GABAA agonist muscimol in the lactacystin model of Parkinson's disease may result from partial lesion of nigral non-dopamine neurons: comparison to the classical neurotoxin 6-OHDA. ( Czarnecka, A; Kamińska, K; Konieczny, J; Lenda, T; Nowak, P, 2015) |
| "The mean Unified Parkinson's Disease Rating Scale scores (UPDRS) and the Parkinson's disease Questionnaire-39 (PDQ-39) were obtained before and after surgery." | 1.42 | Subthalamic Nucleus Deep Brain Stimulation Modulate Catecholamine Levels with Significant Relations to Clinical Outcome after Surgery in Patients with Parkinson's Disease. ( Asahina, M; Higuchi, Y; Hirano, S; Kuwabara, S; Uchiyama, T; Yamamoto, T; Yamanaka, Y, 2015) |
| "The available scientific data indicate that the pathomechanism of Parkinson's disease (PD) involves the accumulation of endogenous and exogenous toxic substances." | 1.39 | Assessment of the role of multidrug resistance-associated proteins in MPTP neurotoxicity in mice. ( Klivényi, P; Plangár, I; Szalárdy, L; Vécsei, L; Zádori, D, 2013) |
| "ADHs are of interest in Parkinson's disease (PD) since these compounds can be harmful to dopamine (DA) neurons." | 1.38 | Adh1 and Adh1/4 knockout mice as possible rodent models for presymptomatic Parkinson's disease. ( Anvret, A; Belin, AC; Duester, G; Felder, MR; Galter, D; Gellhaar, S; Lindqvist, E; Lundströmer, K; Pernold, K; Ran, C; Westerlund, M, 2012) |
| "Idiopathic Parkinson's disease (PD) is a neurodegenerative disorder of mature and older individuals." | 1.36 | Modeling a sensitization stage and a precipitation stage for Parkinson's disease using prenatal and postnatal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration. ( Charlton, CG; King, J; Mackey, V; Muthian, G, 2010) |
| "Our data show that disease progression produces an early large decay of DA levels, followed by a stabilization." | 1.35 | Correlation between changes in CSF dopamine turnover and development of dyskinesia in Parkinson's disease. ( Brusa, L; Fedele, E; Fornai, F; Galati, S; Hainsworth, AH; Lunardi, G; Moschella, V; Pierantozzi, M; Pisani, A; Rossi, S; Stanzione, P; Stefani, A; Tropepi, D, 2009) |
| "The symptoms of restless legs syndrome (RLS) have a circadian pattern and central nervous system dopamine has been implicated in the pathogenesis of the condition." | 1.35 | Circadian rhythm of CSF monoamines and hypocretin-1 in restless legs syndrome and Parkinson's disease. ( Engelland, S; Kripke, DF; Parsons, L; Poceta, JS, 2009) |
| " Because of their ability to combat oxidative stress, diet derived phenolic compounds continue to be considered as potential agents for long-term use in PD." | 1.33 | Neuroprotective properties of the natural phenolic antioxidants curcumin and naringenin but not quercetin and fisetin in a 6-OHDA model of Parkinson's disease. ( Aruoma, OI; Datla, KP; Dexter, DT; Parkar, S; Rai, DK; Zbarsky, V, 2005) |
| "Dopaminergic lesion produced catalepsy and hypoactivity." | 1.32 | Behavioral and neurochemical effects of noradrenergic depletions with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine in 6-hydroxydopamine-induced rat model of Parkinson's disease. ( Schmidt, WJ; Srinivasan, J, 2004) |
| "This syndrome is usually caused by endogenous dopamine deficiency but in these patients was associated with elevated dopamine metabolites in CSF and an unusual eye movement disorder: ocular flutter together with saccade initiation failure." | 1.32 | Infantile Parkinsonism-dystonia and elevated dopamine metabolites in CSF. ( Assmann, BE; Bräutigam, C; Heales, SJ; Hoffmann, GF; Hyland, K; Robinson, RO; Sharma, R; Surtees, RA; Wevers, RA; Zschocke, J, 2004) |
| "Idiopathic Parkinson's disease (PD) is associated with advanced age, but it is still unclear whether dopaminergic neuronal death results from events initiated during development, adulthood, or represents a cumulative effect across the span of life." | 1.31 | Developmental exposure to the pesticides paraquat and maneb and the Parkinson's disease phenotype. ( Baggs, RB; Cory-Slechta, DA; Goodman, BM; Richfield, EK; Thiruchelvam, M, 2002) |
| "The pathogenesis of Parkinson's disease is still an enigma." | 1.31 | N-methyl(R)salsolinol and a neutral N-methyltransferase as pathogenic factors in Parkinson's disease. ( Maruyama, W; Naoi, M; Strolin-Benedetti, M, 2000) |
| "Clinical symptoms of Parkinson's disease (PD) do not manifest until dopamine (DA) neuronal loss reaches a symptomatic threshold." | 1.31 | In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. ( Calne, DB; de la Fuente-Fernandez, R; Holden, JE; Lee, CS; Pal, PK; Ruth, TJ; Samii, A; Schulzer, M; Sossi, V; Stoessl, AJ; Wudel, J, 2000) |
| "Ten patients with advanced Parkinson's disease (Hoehn & Yahr stage IV) were medicated with tolcapone." | 1.31 | COMT-inhibition increases serum levels of dihydroxyphenylacetic acid (DOPAC) in patients with advanced Parkinson's disease. ( Buhmann, C; Oechsner, M; Strauss, J; Stuerenburg, HJ, 2002) |
| "Rapid-onset dystonia-parkinsonism (RDP) is characterized by sudden onset over hours to days of dystonia, dysphagia, dysarthria, and parkinsonism." | 1.30 | Cerebrospinal fluid homovanillic acid levels in rapid-onset dystonia-parkinsonism. ( Brashear, A; Butler, IJ; Dobyns, WB; Farlow, MR; Hyland, K, 1998) |
| "Concentrations of PEA in CSF in Parkinson's disease were significantly lower (mean 205 (SD 131) pg/ml) than in patients with peripheral neuropathy (433 (SD 254) pg/ml) and controls (387 (SD 194) pg/ml)." | 1.30 | Decreased beta-phenylethylamine in CSF in Parkinson's disease. ( Matsuishi, T; Shoji, H; Yamada, S; Zhou, G, 1997) |
| "To determine susceptibility to neuroleptic malignant syndrome (NMS) in patients with PD in relation to central monoamine metabolism." | 1.30 | Susceptibility to neuroleptic malignant syndrome in Parkinson's disease. ( Hamamoto, M; Katayama, Y; Miyazaki, T; Nagayama, H; Nito, C; Otsubo, K; Terashi, A; Ueda, M, 1999) |
| "Distinguishing Alzheimer's disease from DLB is clinically relevant in terms of prognosis and appropriate treatment." | 1.30 | Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution. ( Ballard, C; Burn, D; Court, JA; Jaros, E; Johnson, M; Lloyd, S; Marshall, EF; McKeith, IG; Perry, EK; Perry, RH; Piggott, MA; Thomas, N, 1999) |
| "Investigations of gene therapy for Parkinson's disease have focused primarily on strategies that replace tyrosine hydroxylase." | 1.30 | Role of aromatic L-amino acid decarboxylase for dopamine replacement by genetically modified fibroblasts in a rat model of Parkinson's disease. ( Bencsics, C; Kang, UJ; Wachtel, SR, 1997) |
| "That thalidomide has activity in this model suggests that an inflammatory process may be involved in the induction of lesions by MPTP in DAergic neurons." | 1.30 | Thalidomide reduces MPTP-induced decrease in striatal dopamine levels in mice. ( Boireau, A; Bordier, F; Dubédat, P; Impérato, A; Pény, C, 1997) |
| "There is some evidence that Parkinson's disease (PD) seems to be a heterogenous and generalized brain disorder reflecting a degeneration of multiple neuronal networks, including somatostatinergic neurons." | 1.29 | Somatostatin-like immunoreactivity, its molecular forms and monoaminergic metabolites in aged and demented patients with Parkinson's disease--effect of L-Dopa. ( Cramer, H; Hamann, GF; Schimrigk, K; Strittmatter, M; Strubel, D, 1996) |
| "We report a patient with Meige syndrome (segmental cranial dystonia) who had neuropathologic changes of Parkinson's disease on postmortem examination." | 1.29 | Meige syndrome in the spectrum of Lewy body disease. ( Dickson, DW; Duvoisin, RC; Heikkila, RE; Manzino, L; Mark, MH; Sage, JI; Schwarz, KO, 1994) |
| "In the patient group with visual hallucinations, mean salsolinol level was significantly increased to almost the 3-fold of those found in patients without hallucinations." | 1.29 | Salsolinol, catecholamine metabolites, and visual hallucinations in L-dopa treated patients with Parkinson's disease. ( Jaskowski, P; Kömpf, D; Moser, A; Siebecker, F; Vieregge, P, 1996) |
| " Plasma levodopa and levodopa metabolite pharmacokinetic profiles were determined using standard techniques." | 1.29 | A clinical and pharmacokinetic case study of an interaction of levodopa and antituberculous therapy in Parkinson's disease. ( O'Connell, MT; Patsalos, PN; Quinn, NP; Wenning, GK, 1995) |
| "Patients with the Lewy body variant of Alzheimer's disease tended to experience more frequent extrapyramidal side effects of neuroleptics than did the patients with Alzheimer's disease, but for patients in the two groups who were not exposed to neuroleptics, there was little difference in frequency of extrapyramidal side effects." | 1.29 | Alzheimer's disease and its Lewy body variant: a clinical analysis of postmortem verified cases. ( Cullum, CM; Honig, L; Risser, RC; Rosenberg, RN; Speciale, S; Weiner, MF; White, C, 1996) |
| "Rapid-onset dystonia-parkinsonism (RDP) is an autosomal dominant disorder characterized by the rapid onset of dystonic spasms and parkinsonism over a period of a few hours to weeks after their onset." | 1.29 | Variable phenotype of rapid-onset dystonia-parkinsonism. ( Brashear, A; Butler, IJ; Dobyns, WB; Farlow, MR; Kasarskis, EJ, 1996) |
| "In contrast to senile dementia of Alzheimer's type SLI was not correlated with dementia scores but with motor disease progression." | 1.28 | Parkinson's disease and dementia: clinical and neurochemical correlations. ( Cramer, H; Strittmatter, MM, 1992) |
| "Among Parkinson's disease (PD) patients complaining of pain, 10 with pain not associated with a motor fluctuation or L-dopa therapy were evaluated." | 1.28 | The threshold of pain and neurotransmitter's change on pain in Parkinson's disease. ( Matsushima, E; Nishikawa, S; Sano, K; Takahashi, K; Takao, T; Urakami, K, 1990) |
| " L-DOPA administration, consisting of a daily dosage of 600 mg plus 150 mg aromatic L-amino acid decarboxylase inhibitor was continued in all cases for at least 3 months." | 1.28 | Unresponsiveness to L-DOPA in parkinsonian patients: a study of homovanillic acid concentration in the cerebrospinal fluid. ( Araki, H; Kondo, T; Muramoto, S; Narabayashi, H; Nishi, K; Takubo, H, 1989) |
| "In patients with Parkinson's disease the levels of somatostatin-like immunoreactivity were lower than in controls (P less than ." | 1.28 | Somatostatin-like immunoreactivity in the cerebrospinal fluid of aged patients with Parkinson's disease. The effect of dopatherapy. ( Cramer, H; Kuntzmann, F; Masson, H; Popescu, I; Strubel, D, 1990) |
| "Within the Parkinson's disease group platelet MAO B activity correlated with HVA (an MAO B substrate) but not MHPG (an MAO A substrate)." | 1.27 | Central catecholamine metabolism in vivo and the cognitive and motor deficits in Parkinson's disease. ( Kaplan, RD; Mann, JJ; Neophytides, A; Stanley, M; Sweeney, J, 1983) |
| "Among 49 consecutive patients with Parkinson's disease, 40% were depressed according to DSM-III; they had major depression or dysthymic disorder accompanied by sleep disturbance, fatigue, psychomotor retardation, loss of self-esteem, and excessive guilt." | 1.27 | Clinical and biochemical features of depression in Parkinson's disease. ( Cote, L; Dyrenfurth, I; Frantz, A; Mayeux, R; Stern, Y; Williams, JB, 1986) |
| "In patients with Parkinson's disease the levels of somatostatin-like immunoreactivity were lower than in the controls (p less than 0." | 1.27 | Somatostatin-like immunoreactivity in the cerebrospinal fluid of patients with Parkinson's disease and its relation to dementia. ( Halonen, T; Jolkkonen, J; Laakso, M; Laulumaa, V; Riekkinen, P; Soininen, H; Ylinen, A, 1986) |
| "Patients with Parkinson's disease have a decrement in homovanillic acid that is reversed by treatment with L-3,4-dihydroxyphenylalanine." | 1.27 | Monoamine metabolites in human cerebrospinal fluid. HPLC/ED method. ( Aguado, EG; de Yebenes, JG; Mena, MA, 1984) |
| "Depression is a common symptom in patients with Parkinson's disease." | 1.27 | Altered serotonin metabolism in depressed patients with parkinson's disease. ( Cote, L; Mayeux, R; Stern, Y; Williams, JB, 1984) |
| "Thirty-four patients with advanced Parkinson's disease showing intolerance to therapeutic doses of L-DOPA were treated with L-DOPA plus carbidopa at two different proportions." | 1.27 | Carbidopa dosage modifies L-dopa induced side effects and blood levels of L-dopa and other amino acids in advanced parkinsonism. ( Bermejo Pareja, F; de Yébenes, JG; Martinez-Martin, P; Muradas, V, 1985) |
| "2." | 1.26 | Dopamine in thelimbic regions of the human brain: normal and abnormal. ( Farley, IJ; Hornykiewicz, O; Price, KS, 1977) |
| "compensated stage of Parkinson's disease)." | 1.26 | CNS compensation to dopamine neuron loss in Parkinson's disease. ( Lloyd, KG, 1977) |
| "Six patients with Parkinson's disease and five controls were premedicated with probenecid and the peripheral decarboxylase inhibitor alpha-methyldopathydrazine (Carbidopa) before intravenous administration of 50 muc of 14C-L-dopa in tracer quantity." | 1.26 | 14C-homovanillic acid in the cerebrospinal fluid of parkinsonian patients after intravenous 14C-L-dopa. ( Bowers, MB; Extein, I; Roth, RH; Van Woert, M, 1976) |
| "Patients with Huntington's chorea showed a low level of the HVA in the intraventricular fluid." | 1.26 | [Approaches to the study of dopamine metabolism in various extrapyramidal diseases]. ( Barkhatova, VP; Demina, EG; Kandel', EI, 1981) |
| "Treatment with tetrabenazine did not significantly alter the metabolite levels in patients in whom it produced either improvement, or side effects." | 1.26 | CSF studies on the relationship between dopamine and 5-hydroxytryptamine in Parkinsonism and other movement disorders. ( Davidson, DL; Mawdsley, C; Pullar, IA; Wilson, H; Yates, CM, 1977) |
| "Probenecid was administered to 7 unipolar depressed patients, 7 parkinsonians and 7 extrapyramidal patients with senile dementia matched for age and sex." | 1.26 | Serotonin and dopamine disturbances in patients with unipolar depression and Parkinsonism. ( Mendlewicz, J; Noel, G; Vanderheyden, JE, 1981) |
| "Lethargy and mental depression are early symptoms, followed by mild parkinsonism and progressive weight loss." | 1.26 | Familial fatal Parkinsonism with alveolar hypoventilation and mental depression. ( Ahmad, D; Barnett, HJ; Bratty, P; Hahn, A; Lloyd, KG; McGeer, EG; Perry, TL; Purdy, A, 1979) |
| "We believe that neuropharmacologic bladder neck obstruction may be caused by the alpha-adrenergic properties of the metabolites of levodopa." | 1.25 | Effects of levodopa on the bladder outlet. ( Krane, RJ; Murdock, MI; Olsson, CA; Sax, DS, 1975) |
| "Levodopa induced an increase of about 400 fold in urinary DA; DOPAC was increased about 300 fold, 3-MT only about 70 fold, but HVA about 300 fold." | 1.25 | Urinary excretion of monoamines and their metabolites in patients with Parkinson's disease. Response to long-term treatment with levodopa alone or in combination with a dopa decarboxylase inhibitor and clinical correlations. ( Rinne, UK; Siirtola, T; Sonninen, V, 1975) |
| "Twenty-seven patients with Parkinson's disease participated in a double-blind crossover trial of L-dopa and amantadine." | 1.25 | Interactions of L-dopa and amantadine in patients with Parkinsonism. ( Cox, B; Danta, G; Schnieden, H; Yuill, GM, 1973) |
| "Six patients diagnosed as Parkinson's disease on a clinical basis alone are described, and their response to L-dopa and to alpha methyl dopa hydrazine (MK 486) and L-dopa." | 1.25 | An analysis of six patients with Parkinson's disease who have been unresponsive to L-dopa therapy. ( Mones, RJ, 1973) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 171 (51.35) | 18.7374 |
| 1990's | 79 (23.72) | 18.2507 |
| 2000's | 40 (12.01) | 29.6817 |
| 2010's | 38 (11.41) | 24.3611 |
| 2020's | 5 (1.50) | 2.80 |
| Authors | Studies |
|---|---|
| Zhou, J | 1 |
| Li, J | 1 |
| Papaneri, AB | 1 |
| Cui, G | 1 |
| Goto, R | 1 |
| Kurihara, M | 1 |
| Kameyama, M | 1 |
| Komatsu, H | 1 |
| Higashino, M | 1 |
| Hatano, K | 1 |
| Ihara, R | 1 |
| Higashihara, M | 1 |
| Nishina, Y | 1 |
| Matsubara, T | 1 |
| Kanemaru, K | 4 |
| Saito, Y | 2 |
| Murayama, S | 2 |
| Iwata, A | 1 |
| Yang, R | 1 |
| Ye, S | 1 |
| Zhang, S | 1 |
| Huang, H | 1 |
| Zhang, Y | 1 |
| Yang, Y | 2 |
| Xie, S | 1 |
| He, L | 1 |
| Shi, J | 1 |
| Goldstein, DS | 2 |
| Sullivan, P | 1 |
| Holmes, C | 1 |
| Lamotte, G | 1 |
| Lenka, A | 1 |
| Sharabi, Y | 1 |
| Kremer, T | 1 |
| Taylor, KI | 1 |
| Siebourg-Polster, J | 1 |
| Gerken, T | 1 |
| Staempfli, A | 1 |
| Czech, C | 1 |
| Dukart, J | 1 |
| Galasko, D | 1 |
| Foroud, T | 1 |
| Chahine, LM | 1 |
| Coffey, CS | 1 |
| Simuni, T | 1 |
| Weintraub, D | 1 |
| Seibyl, J | 1 |
| Poston, KL | 1 |
| Toga, AW | 1 |
| Tanner, CM | 1 |
| Marek, K | 1 |
| Hutten, SJ | 1 |
| Dziadek, S | 1 |
| Trenkwalder, C | 1 |
| Pagano, G | 1 |
| Mollenhauer, B | 1 |
| Liu, J | 2 |
| Zheng, F | 1 |
| Long, Y | 1 |
| Tong, L | 1 |
| Zheng, Y | 1 |
| Liu, X | 2 |
| Qin, C | 2 |
| Uemura, MT | 1 |
| Asano, T | 1 |
| Hikawa, R | 1 |
| Yamakado, H | 1 |
| Takahashi, R | 1 |
| van der Zee, S | 1 |
| Vermeiren, Y | 1 |
| Fransen, E | 1 |
| Van Dam, D | 1 |
| Aerts, T | 1 |
| Gerritsen, MJ | 1 |
| Spikman, JM | 1 |
| van Laar, T | 1 |
| De Deyn, PP | 1 |
| Kulikova, OI | 1 |
| Berezhnoy, DS | 1 |
| Stvolinsky, SL | 1 |
| Lopachev, AV | 1 |
| Orlova, VS | 1 |
| Fedorova, TN | 1 |
| Cheng, S | 1 |
| Tereshchenko, J | 1 |
| Zimmer, V | 1 |
| Vachey, G | 1 |
| Pythoud, C | 1 |
| Rey, M | 1 |
| Liefhebber, J | 1 |
| Raina, A | 1 |
| Streit, F | 1 |
| Mazur, A | 1 |
| Bähr, M | 3 |
| Konstantinova, P | 1 |
| Déglon, N | 1 |
| Kügler, S | 1 |
| Joniec-Maciejak, I | 1 |
| Wawer, A | 1 |
| Turzyńska, D | 1 |
| Sobolewska, A | 1 |
| Maciejak, P | 1 |
| Szyndler, J | 1 |
| Mirowska-Guzel, D | 1 |
| Płaźnik, A | 1 |
| Pagan, FL | 1 |
| Hebron, ML | 1 |
| Wilmarth, B | 1 |
| Torres-Yaghi, Y | 1 |
| Lawler, A | 1 |
| Mundel, EE | 1 |
| Yusuf, N | 1 |
| Starr, NJ | 1 |
| Arellano, J | 1 |
| Howard, HH | 1 |
| Peyton, M | 1 |
| Matar, S | 1 |
| Fowler, AJ | 1 |
| Schwartz, SL | 1 |
| Ahn, J | 1 |
| Moussa, C | 1 |
| Petri, D | 1 |
| Pum, M | 1 |
| Vesper, J | 1 |
| Huston, JP | 1 |
| Schnitzler, A | 1 |
| Han, B | 2 |
| Hu, J | 1 |
| Shen, J | 1 |
| Gao, Y | 1 |
| Lu, Y | 1 |
| Wang, T | 2 |
| Herbert, MK | 1 |
| Kuiperij, H | 1 |
| Bloem, BR | 2 |
| Verbeek, MM | 2 |
| Yamamoto, T | 2 |
| Uchiyama, T | 2 |
| Sakakibara, R | 1 |
| Taniguchi, J | 1 |
| Kuwabara, S | 2 |
| Szkilnik, R | 1 |
| Brus, R | 1 |
| Malinowska-Borowska, J | 1 |
| Nowak, D | 1 |
| Waliczek, M | 1 |
| Kostrzewa, RM | 1 |
| Nowak, P | 2 |
| Plangár, I | 1 |
| Zádori, D | 1 |
| Szalárdy, L | 1 |
| Vécsei, L | 1 |
| Klivényi, P | 1 |
| Feng, G | 1 |
| Zhang, Z | 2 |
| Bao, Q | 1 |
| Zhou, L | 1 |
| Jiang, J | 1 |
| Li, S | 1 |
| Pifl, C | 1 |
| Rajput, A | 3 |
| Reither, H | 1 |
| Blesa, J | 1 |
| Cavada, C | 1 |
| Obeso, JA | 1 |
| Rajput, AH | 1 |
| Hornykiewicz, O | 11 |
| Jin, HJ | 1 |
| Song, MY | 1 |
| Zhao, H | 1 |
| Nordströma, U | 1 |
| Beauvais, G | 1 |
| Ghosh, A | 1 |
| Pulikkaparambil Sasidharan, BC | 1 |
| Lundblad, M | 1 |
| Fuchs, J | 1 |
| Joshi, RL | 1 |
| Lipton, JW | 1 |
| Roholt, A | 1 |
| Medicetty, S | 1 |
| Feinstein, TN | 1 |
| Steiner, JA | 1 |
| Escobar Galvis, ML | 1 |
| Prochiantz, A | 1 |
| Brundin, P | 1 |
| Wolff, EF | 1 |
| Mutlu, L | 1 |
| Massasa, EE | 1 |
| Elsworth, JD | 3 |
| Eugene Redmond, D | 1 |
| Taylor, HS | 1 |
| Saal, KA | 1 |
| Koch, JC | 1 |
| Tatenhorst, L | 1 |
| Szegő, EM | 1 |
| Ribas, VT | 1 |
| Michel, U | 1 |
| Tönges, L | 1 |
| Lingor, P | 1 |
| Konieczny, J | 1 |
| Czarnecka, A | 1 |
| Kamińska, K | 1 |
| Lenda, T | 1 |
| Sharma, N | 1 |
| Nehru, B | 1 |
| Higuchi, Y | 1 |
| Asahina, M | 1 |
| Hirano, S | 1 |
| Yamanaka, Y | 1 |
| Rai, SN | 1 |
| Yadav, SK | 1 |
| Singh, D | 1 |
| Singh, SP | 1 |
| Stefani, A | 2 |
| Pierantozzi, M | 2 |
| Olivola, E | 1 |
| Galati, S | 2 |
| Cerroni, R | 1 |
| D'Angelo, V | 1 |
| Hainsworth, AH | 2 |
| Saviozzi, V | 1 |
| Fedele, E | 2 |
| Liguori, C | 1 |
| Andersen, AD | 1 |
| Blaabjerg, M | 1 |
| Binzer, M | 1 |
| Kamal, A | 1 |
| Thagesen, H | 1 |
| Kjaer, TW | 1 |
| Stenager, E | 1 |
| Gramsbergen, JBP | 1 |
| Xu, L | 1 |
| Liu, LX | 1 |
| Chen, WF | 1 |
| Lunardi, G | 1 |
| Tropepi, D | 1 |
| Moschella, V | 1 |
| Brusa, L | 1 |
| Rossi, S | 1 |
| Fornai, F | 1 |
| Stanzione, P | 1 |
| Pisani, A | 1 |
| Yano, R | 1 |
| Yokoyama, H | 1 |
| Kuroiwa, H | 1 |
| Kato, H | 1 |
| Araki, T | 1 |
| Pålhagen, S | 1 |
| Qi, H | 1 |
| Mårtensson, B | 1 |
| Wålinder, J | 2 |
| Granérus, AK | 4 |
| Svenningsson, P | 1 |
| Ishibashi, K | 1 |
| Oda, K | 1 |
| Ishiwata, K | 1 |
| Mizusawa, H | 1 |
| Ishii, K | 1 |
| Hunter, RL | 1 |
| Liu, M | 1 |
| Choi, DY | 1 |
| Cass, WA | 1 |
| Bing, G | 1 |
| Marcellino, D | 1 |
| Suárez-Boomgaard, D | 1 |
| Sánchez-Reina, MD | 1 |
| Aguirre, JA | 1 |
| Yoshitake, T | 1 |
| Yoshitake, S | 1 |
| Hagman, B | 1 |
| Kehr, J | 1 |
| Agnati, LF | 1 |
| Fuxe, K | 1 |
| Rivera, A | 1 |
| Muthian, G | 1 |
| Mackey, V | 1 |
| King, J | 1 |
| Charlton, CG | 1 |
| Nyhlén, J | 1 |
| Constantinescu, R | 1 |
| Zetterberg, H | 1 |
| Belin, AC | 2 |
| Westerlund, M | 2 |
| Anvret, A | 2 |
| Lindqvist, E | 2 |
| Pernold, K | 2 |
| Ogren, SO | 1 |
| Duester, G | 2 |
| Galter, D | 2 |
| Wang, H | 1 |
| Zhang, L | 1 |
| Xu, Y | 1 |
| Deng, W | 1 |
| Zhu, H | 1 |
| LeWitt, P | 2 |
| Schultz, L | 1 |
| Auinger, P | 1 |
| Lu, M | 1 |
| Ran, C | 1 |
| Gellhaar, S | 1 |
| Lundströmer, K | 1 |
| Felder, MR | 1 |
| Meng, T | 1 |
| Zheng, ZH | 1 |
| Liu, TT | 1 |
| Lin, L | 1 |
| Liu, SM | 1 |
| Li, XZ | 1 |
| Huo, Y | 1 |
| Lu, F | 1 |
| Frank, T | 1 |
| Klinker, F | 1 |
| Falkenburger, BH | 1 |
| Laage, R | 1 |
| Lühder, F | 1 |
| Göricke, B | 1 |
| Schneider, A | 1 |
| Neurath, H | 1 |
| Desel, H | 1 |
| Liebetanz, D | 1 |
| Weishaupt, JH | 1 |
| Linazasoro, G | 2 |
| Indakoetxea, B | 1 |
| Ruiz, J | 1 |
| Van Blercom, N | 2 |
| Lasa, A | 1 |
| McCormack, AL | 1 |
| Thiruchelvam, M | 2 |
| Manning-Bog, AB | 1 |
| Thiffault, C | 1 |
| Langston, JW | 1 |
| Cory-Slechta, DA | 2 |
| Di Monte, DA | 1 |
| Yamanouchi, H | 2 |
| Richfield, EK | 1 |
| Goodman, BM | 1 |
| Baggs, RB | 1 |
| Kaur, D | 1 |
| Yantiri, F | 1 |
| Rajagopalan, S | 1 |
| Kumar, J | 1 |
| Mo, JQ | 1 |
| Boonplueang, R | 1 |
| Viswanath, V | 1 |
| Jacobs, R | 1 |
| Yang, L | 1 |
| Beal, MF | 2 |
| DiMonte, D | 1 |
| Volitaskis, I | 1 |
| Ellerby, L | 1 |
| Cherny, RA | 1 |
| Bush, AI | 1 |
| Andersen, JK | 1 |
| Jähnel, M | 1 |
| Burke, WJ | 1 |
| Li, SW | 1 |
| Williams, EA | 1 |
| Nonneman, R | 1 |
| Zahm, DS | 1 |
| Srinivasan, J | 1 |
| Schmidt, WJ | 1 |
| Youdim, MB | 1 |
| Stephenson, G | 1 |
| Ben Shachar, D | 1 |
| Abdo, WF | 1 |
| De Jong, D | 1 |
| Hendriks, JC | 1 |
| Horstink, MW | 1 |
| Kremer, BP | 1 |
| Assmann, BE | 1 |
| Robinson, RO | 1 |
| Surtees, RA | 1 |
| Bräutigam, C | 1 |
| Heales, SJ | 1 |
| Wevers, RA | 1 |
| Zschocke, J | 1 |
| Hyland, K | 2 |
| Sharma, R | 1 |
| Hoffmann, GF | 1 |
| Gluck, MR | 2 |
| Santana, LA | 1 |
| Granson, H | 1 |
| Yahr, MD | 3 |
| Zeevalk, GD | 1 |
| Asanuma, M | 2 |
| Miyazaki, I | 1 |
| Diaz-Corrales, FJ | 1 |
| Shimizu, M | 1 |
| Tanaka, K | 2 |
| Ogawa, N | 2 |
| Zbarsky, V | 1 |
| Datla, KP | 1 |
| Parkar, S | 1 |
| Rai, DK | 1 |
| Aruoma, OI | 1 |
| Dexter, DT | 2 |
| Jiang, H | 2 |
| Jiang, Q | 1 |
| Liu, W | 1 |
| Feng, J | 1 |
| Fitzsimmons, DF | 1 |
| Moloney, TC | 1 |
| Dowd, E | 1 |
| Landau, AM | 1 |
| Kouassi, E | 1 |
| Siegrist-Johnstone, R | 1 |
| Desbarats, J | 1 |
| Grandoso, L | 1 |
| Ponce, S | 1 |
| Manuel, I | 1 |
| Arrúe, A | 1 |
| Ruiz-Ortega, JA | 1 |
| Ulibarri, I | 1 |
| Orive, G | 1 |
| Hernández, RM | 1 |
| Rodríguez, A | 1 |
| Rodríguez-Puertas, R | 1 |
| Zumárraga, M | 1 |
| Pedraz, JL | 1 |
| Ugedo, L | 1 |
| Davidson, DF | 1 |
| Grosset, K | 1 |
| Grosset, D | 1 |
| Poceta, JS | 1 |
| Parsons, L | 1 |
| Engelland, S | 1 |
| Kripke, DF | 1 |
| Mayeux, R | 6 |
| Melamed, E | 4 |
| Hefti, F | 3 |
| Liebman, J | 1 |
| Schlosberg, AJ | 1 |
| Wurtman, RJ | 4 |
| De Mattos, JP | 1 |
| Cechela, C | 1 |
| Adams, JG | 1 |
| De Lima, JM | 1 |
| Willner, P | 1 |
| Colucci d'Amato, C | 1 |
| Puccini, A | 1 |
| Cristillo, A | 1 |
| Vizioli, R | 1 |
| Agnoli, A | 2 |
| Ruggieri, S | 2 |
| Falaschi, P | 1 |
| Baldassarre, M | 1 |
| D'Urso, R | 1 |
| Forchetti, C | 1 |
| Polleri, A | 1 |
| Eisler, T | 1 |
| Teräväinen, H | 1 |
| Nelson, R | 1 |
| Krebs, H | 1 |
| Weise, V | 1 |
| Lake, CR | 1 |
| Ebert, MH | 4 |
| Whetzel, N | 1 |
| Murphy, DL | 1 |
| Kopin, IJ | 5 |
| Calne, DB | 6 |
| Vanderheyden, JE | 2 |
| Noel, G | 2 |
| Mendlewicz, J | 2 |
| Growdon, JH | 2 |
| Logue, M | 2 |
| Markianos, M | 3 |
| Hadjikonstantinou, M | 3 |
| Bistolaki, E | 1 |
| Burns, RS | 3 |
| Chiueh, CC | 1 |
| Markey, SP | 1 |
| Jacobowitz, DM | 1 |
| Cramer, H | 5 |
| Warter, JM | 1 |
| Renaud, B | 1 |
| Pezzoli, G | 1 |
| Panerai, AE | 1 |
| Di Giulio, A | 1 |
| Longo, A | 1 |
| Passerini, D | 1 |
| Carenzi, A | 1 |
| Stern, Y | 5 |
| Cote, L | 5 |
| Williams, JB | 4 |
| Mena, MA | 2 |
| Aguado, EG | 1 |
| de Yebenes, JG | 2 |
| Barkhatova, VP | 1 |
| Kandel', EI | 1 |
| Demina, EG | 1 |
| Direnfeld, LK | 3 |
| Albert, ML | 4 |
| Volicer, L | 4 |
| Langlais, PJ | 2 |
| Marquis, J | 1 |
| Kaplan, E | 1 |
| Mann, JJ | 1 |
| Stanley, M | 1 |
| Kaplan, RD | 1 |
| Sweeney, J | 1 |
| Neophytides, A | 1 |
| Bokobza, B | 1 |
| Ruberg, M | 1 |
| Scatton, B | 4 |
| Javoy-Agid, F | 5 |
| Agid, Y | 2 |
| Liu, DK | 2 |
| Cunha, L | 1 |
| Gonçalves, AF | 1 |
| Oliveira, C | 1 |
| Dinis, M | 1 |
| Amaral, R | 1 |
| Reches, A | 1 |
| Fahn, S | 3 |
| Rouquier, L | 1 |
| Sfagos, C | 1 |
| Bierer, DW | 1 |
| Quebbemann, AJ | 1 |
| Muthane, UB | 2 |
| Swamy, HS | 1 |
| Satishchandra, P | 2 |
| Subhash, MN | 2 |
| Rao, S | 1 |
| Subbakrishna, D | 1 |
| Ishikawa, A | 1 |
| Miyatake, T | 2 |
| Tohgi, H | 3 |
| Abe, T | 2 |
| Yamazaki, K | 1 |
| Saheki, M | 1 |
| Takahashi, S | 1 |
| Tsukamoto, Y | 1 |
| Moser, A | 2 |
| Scholz, J | 1 |
| Nobbe, F | 1 |
| Vieregge, P | 2 |
| Böhme, V | 1 |
| Bamberg, H | 1 |
| Loeffler, DA | 1 |
| LeWitt, PA | 4 |
| DeMaggio, AJ | 1 |
| Juneau, PL | 1 |
| Milbury, PE | 1 |
| Matson, WR | 1 |
| Amalric, M | 1 |
| Moukhles, H | 1 |
| Nieoullon, A | 2 |
| Daszuta, A | 1 |
| Finberg, JP | 1 |
| Wang, J | 1 |
| Bankiewicz, KS | 2 |
| Espino, A | 1 |
| Llorens, J | 1 |
| Calopa, M | 1 |
| Bartrons, R | 1 |
| Rodriguez-Farré, E | 1 |
| Ambrosio, S | 1 |
| Mitsui, T | 1 |
| Kawai, H | 1 |
| Sakoda, S | 1 |
| Miyata, M | 1 |
| Saito, S | 1 |
| Muthane, U | 1 |
| Ramsay, KA | 1 |
| Jackson-Lewis, V | 2 |
| Donaldson, D | 1 |
| Fernando, S | 1 |
| Ferreira, M | 1 |
| Przedborski, S | 3 |
| Mark, MH | 1 |
| Sage, JI | 1 |
| Dickson, DW | 1 |
| Heikkila, RE | 2 |
| Manzino, L | 1 |
| Schwarz, KO | 1 |
| Duvoisin, RC | 1 |
| Myllylä, VV | 1 |
| Sotaniemi, KA | 1 |
| Illi, A | 1 |
| Suominen, K | 1 |
| Keränen, T | 1 |
| Hossain, MA | 1 |
| Weiner, N | 1 |
| Sian, J | 1 |
| Rose, S | 2 |
| Hindmarsh, JG | 2 |
| Mann, VM | 1 |
| Cooper, JM | 1 |
| Wells, FR | 1 |
| Daniel, SE | 1 |
| Lees, AJ | 1 |
| Schapira, AH | 1 |
| Jenner, P | 3 |
| Kondo, T | 2 |
| Benetello, P | 1 |
| Furlanut, M | 1 |
| Zara, G | 1 |
| Baraldo, M | 1 |
| Hassan, E | 1 |
| Merchant, CA | 1 |
| Cohen, G | 1 |
| Mytilineou, C | 1 |
| DiRocco, A | 1 |
| Moros, D | 1 |
| Molinari, S | 1 |
| Wenning, GK | 1 |
| O'Connell, MT | 1 |
| Patsalos, PN | 1 |
| Quinn, NP | 2 |
| Yokoyama, R | 1 |
| Shibata, T | 1 |
| Dawson, VL | 1 |
| Dawson, TM | 1 |
| Brashear, A | 4 |
| Farlow, MR | 4 |
| Butler, IJ | 3 |
| Kasarskis, EJ | 1 |
| Dobyns, WB | 3 |
| Maruyama, W | 3 |
| Dostert, P | 1 |
| Naoi, M | 3 |
| Ruottinen, HM | 1 |
| Rinne, UK | 10 |
| Strittmatter, M | 1 |
| Hamann, GF | 1 |
| Strubel, D | 2 |
| Schimrigk, K | 1 |
| Weiner, MF | 1 |
| Risser, RC | 1 |
| Cullum, CM | 1 |
| Honig, L | 1 |
| White, C | 1 |
| Speciale, S | 1 |
| Rosenberg, RN | 2 |
| Narabayashi, H | 2 |
| Howells, DW | 1 |
| Liberatore, GT | 1 |
| Wong, JY | 1 |
| Donnan, GA | 1 |
| Bowers, MB | 2 |
| Dethy, S | 1 |
| Laute, MA | 1 |
| Damhaut, P | 1 |
| Goldman, S | 1 |
| Hildebrand, J | 2 |
| Antkiewicz-Michaluk, L | 2 |
| Krygowska-Wajs, A | 1 |
| Szczudlik, A | 1 |
| Romańska, I | 2 |
| Vetulani, J | 2 |
| Iacono, RP | 2 |
| Kuniyoshi, SM | 1 |
| Ahlman, JR | 1 |
| Zimmerman, GJ | 1 |
| Maeda, G | 1 |
| Pearlstein, RD | 1 |
| Durso, R | 5 |
| Evans, JE | 1 |
| Josephs, E | 1 |
| Szabo, GK | 3 |
| Evans, BA | 1 |
| Handler, JS | 1 |
| Jennings, D | 1 |
| Browne, TR | 1 |
| Steiger, MJ | 1 |
| Bhatt, M | 1 |
| Marsden, CD | 3 |
| Wachtel, SR | 1 |
| Bencsics, C | 1 |
| Kang, UJ | 1 |
| Boireau, A | 1 |
| Bordier, F | 1 |
| Dubédat, P | 1 |
| Pény, C | 1 |
| Impérato, A | 1 |
| Zhou, G | 1 |
| Shoji, H | 2 |
| Yamada, S | 1 |
| Matsuishi, T | 1 |
| Mitani, K | 1 |
| Yoshida, K | 1 |
| Higuchi, H | 1 |
| Kamata, M | 1 |
| Yoshimoto, M | 1 |
| Shimizu, T | 1 |
| Hishikawa, Y | 1 |
| Siebecker, F | 1 |
| Jaskowski, P | 1 |
| Kömpf, D | 1 |
| Cheng, FC | 1 |
| Kuo, JS | 1 |
| Chia, LG | 1 |
| Dryhurst, G | 1 |
| Brannan, T | 1 |
| Prikhojan, A | 1 |
| Martínez-Tica, J | 1 |
| Fall, PA | 1 |
| Ekman, R | 1 |
| Thorell, LH | 1 |
| Muenter, MD | 3 |
| Forno, LS | 1 |
| Kish, SJ | 2 |
| Maraganore, DM | 1 |
| Caselli, RJ | 1 |
| Okazaki, H | 1 |
| Howard, FM | 1 |
| Snow, BJ | 1 |
| Izurieta-Sánchez, P | 1 |
| Sarre, S | 1 |
| Ebinger, G | 2 |
| Michotte, Y | 1 |
| Ozelius, LJ | 1 |
| Kramer, PI | 1 |
| Breakefield, XO | 1 |
| Piggott, MA | 2 |
| Perry, EK | 3 |
| Marshall, EF | 2 |
| McKeith, IG | 2 |
| Johnson, M | 2 |
| Melrose, HL | 1 |
| Court, JA | 2 |
| Lloyd, S | 2 |
| Fairbairn, A | 1 |
| Brown, A | 1 |
| Thompson, P | 2 |
| Perry, RH | 2 |
| Mulholland, GK | 1 |
| Zheng, QH | 1 |
| Siemers, ER | 1 |
| Hutchins, GD | 1 |
| Ueda, M | 2 |
| Hamamoto, M | 2 |
| Nagayama, H | 2 |
| Otsubo, K | 1 |
| Nito, C | 1 |
| Miyazaki, T | 1 |
| Terashi, A | 1 |
| Katayama, Y | 2 |
| Thomas, N | 1 |
| Jaros, E | 1 |
| Burn, D | 1 |
| Ballard, C | 1 |
| Lee, CS | 1 |
| Samii, A | 1 |
| Sossi, V | 1 |
| Ruth, TJ | 1 |
| Schulzer, M | 1 |
| Holden, JE | 1 |
| Wudel, J | 1 |
| Pal, PK | 1 |
| de la Fuente-Fernandez, R | 1 |
| Stoessl, AJ | 1 |
| Nahab, FB | 1 |
| Nahab, FH | 1 |
| Serra, PA | 1 |
| Esposito, G | 1 |
| Enrico, P | 1 |
| Mura, MA | 1 |
| Migheli, R | 1 |
| Delogu, MR | 1 |
| Miele, M | 1 |
| Desole, MS | 1 |
| Grella, G | 1 |
| Miele, E | 1 |
| Strolin-Benedetti, M | 1 |
| Michaluk, J | 1 |
| Papla, I | 1 |
| Meissner, W | 1 |
| Paul, G | 1 |
| Reum, T | 1 |
| Reese, R | 1 |
| Sohr, R | 1 |
| Morgenstern, R | 1 |
| Kupsch, A | 1 |
| Rathke-Hartlieb, S | 1 |
| Kahle, PJ | 1 |
| Neumann, M | 1 |
| Ozmen, L | 1 |
| Haid, S | 1 |
| Okochi, M | 1 |
| Haass, C | 1 |
| Schulz, JB | 1 |
| Tillerson, JL | 1 |
| Cohen, AD | 1 |
| Philhower, J | 1 |
| Miller, GW | 1 |
| Zigmond, MJ | 1 |
| Schallert, T | 1 |
| Okubo, S | 1 |
| Amemiya, S | 1 |
| Abe, K | 1 |
| Taguchi, K | 1 |
| Wasai, T | 1 |
| Ren, J | 1 |
| Utsunomiya, I | 1 |
| Shinohara, T | 1 |
| Sano, T | 1 |
| Shimamoto, H | 1 |
| Takasaki, K | 1 |
| Shigemori, M | 1 |
| Imaizumi, T | 1 |
| Ayabe, M | 1 |
| Barthwal, MK | 1 |
| Srivastava, N | 1 |
| Dikshit, M | 1 |
| Oechsner, M | 1 |
| Buhmann, C | 1 |
| Strauss, J | 1 |
| Stuerenburg, HJ | 1 |
| Gramsbergen, JB | 1 |
| Sandberg, M | 1 |
| Møller Dall, A | 1 |
| Kornblit, B | 1 |
| Zimmer, J | 1 |
| Lloyd, KG | 4 |
| Davidson, L | 1 |
| Costentin, J | 1 |
| Purdy, A | 1 |
| Hahn, A | 1 |
| Barnett, HJ | 1 |
| Bratty, P | 1 |
| Ahmad, D | 1 |
| McGeer, EG | 1 |
| Perry, TL | 1 |
| Moskowitz, MA | 1 |
| Klawans, H | 1 |
| Kartzinel, R | 2 |
| Chase, TN | 13 |
| Perlow, MD | 1 |
| Carter, AC | 1 |
| Shoulson, I | 3 |
| Klawans, HL | 3 |
| Goetz, C | 1 |
| Nausieda, PA | 2 |
| Weiner, WJ | 2 |
| Peringer, E | 1 |
| Korf, J | 4 |
| van Praagen, HM | 1 |
| Lakke, JP | 3 |
| Ogawa, M | 1 |
| Lovenberg, W | 1 |
| Levine, RA | 1 |
| Robinson, DS | 1 |
| Ebert, M | 1 |
| Williams, AC | 1 |
| Mizuno, Y | 1 |
| Ariga, T | 1 |
| Morrisey, JL | 1 |
| Shihabi, ZK | 1 |
| Tabaddor, K | 1 |
| Wolfson, LI | 3 |
| Sharpless, NS | 4 |
| Ouvrier, RA | 1 |
| Davidson, DL | 1 |
| Yates, CM | 1 |
| Mawdsley, C | 1 |
| Pullar, IA | 2 |
| Wilson, H | 1 |
| Wiener, WJ | 1 |
| Kramer, J | 1 |
| Peyrin, L | 2 |
| Cottet-Emard, JM | 2 |
| Claustre, B | 1 |
| Lee, T | 1 |
| Seeman, P | 1 |
| Farley, IJ | 3 |
| Price, KS | 2 |
| Marttila, R | 4 |
| Naidu, S | 1 |
| Siirtola, T | 3 |
| Sonninen, V | 7 |
| Bianchine, JR | 1 |
| Shaw, GM | 1 |
| Narasimhachari, N | 1 |
| Leiner, K | 1 |
| Brown, C | 1 |
| Poirier, LJ | 1 |
| Parent, A | 1 |
| Roberge, AG | 1 |
| Sachdev, KK | 1 |
| Singh, N | 1 |
| Krishnamoorthy, MS | 1 |
| Lhermitte, F | 2 |
| Rosa, A | 2 |
| Comoy, E | 2 |
| Campanella, G | 2 |
| Algeri, S | 1 |
| Cerletti, C | 1 |
| Dolfini, E | 1 |
| Jori, A | 1 |
| Rinaldi, F | 1 |
| Lenman, JA | 2 |
| Turnbull, MJ | 2 |
| Reid, A | 1 |
| Fleming, AM | 1 |
| Hoehn, MM | 4 |
| Crowley, TJ | 2 |
| Rutledge, CO | 4 |
| Allen, N | 1 |
| Knopp, W | 1 |
| Nyhan, WL | 1 |
| Bay, C | 1 |
| Shore, P | 1 |
| Michel, D | 1 |
| Tommasi, M | 1 |
| Laurent, B | 1 |
| Trillet, M | 1 |
| Schott, B | 1 |
| Extein, I | 1 |
| Van Woert, M | 1 |
| Roth, RH | 4 |
| Isgreen, WP | 1 |
| Chutorian, AM | 1 |
| McLellan, DL | 1 |
| Chalmers, RJ | 1 |
| Johnson, RH | 1 |
| Bronaugh, RL | 1 |
| MacMurtry, RJ | 1 |
| Murdock, MI | 1 |
| Olsson, CA | 1 |
| Sax, DS | 1 |
| Krane, RJ | 1 |
| Watson, E | 1 |
| Wilk, S | 1 |
| Praag, HM | 1 |
| Schut, T | 2 |
| Lach, B | 1 |
| Grimes, D | 1 |
| Benoit, B | 1 |
| Minkiewicz-Janda, A | 1 |
| Strittmatter, MM | 1 |
| Spencer, DD | 1 |
| Robbins, RJ | 1 |
| Naftolin, F | 1 |
| Marek, KL | 1 |
| Vollmer, T | 1 |
| Leranth, C | 1 |
| Price, LH | 1 |
| Gjedde, A | 1 |
| Bunney, BS | 1 |
| Galloway, MP | 1 |
| Matson, W | 1 |
| Milbury, P | 1 |
| McDermott, M | 1 |
| Srivastava, DK | 1 |
| Oakes, D | 1 |
| Moussa, Z | 1 |
| Raftopoulos, C | 1 |
| Baronti, F | 1 |
| Conant, KE | 1 |
| Giuffra, M | 1 |
| Davis, TL | 1 |
| Brughitta, G | 1 |
| Iadarola, MJ | 1 |
| Berrettini, WH | 1 |
| Mouradian, MM | 1 |
| Masson, H | 1 |
| Popescu, I | 1 |
| Kuntzmann, F | 1 |
| Guttman, M | 1 |
| Fibiger, HC | 1 |
| Jakubovic, A | 1 |
| Lindvall, B | 1 |
| Olsson, JE | 1 |
| Przuntek, H | 3 |
| Kuhn, W | 2 |
| Plunkett, RJ | 1 |
| Mefford, I | 1 |
| Oldfield, EH | 1 |
| Urakami, K | 1 |
| Takahashi, K | 1 |
| Matsushima, E | 1 |
| Sano, K | 1 |
| Nishikawa, S | 1 |
| Takao, T | 1 |
| Russ, H | 1 |
| Mihatsch, W | 1 |
| Gerlach, M | 1 |
| Riederer, P | 3 |
| Sofic, E | 2 |
| Gsell, W | 2 |
| Gavranovic, M | 1 |
| Schmidtke, A | 1 |
| Jellinger, K | 2 |
| McKeith, I | 1 |
| Marshall, E | 1 |
| Kerwin, J | 1 |
| Jabeen, S | 1 |
| Edwardson, JA | 1 |
| Ince, P | 1 |
| Blessed, G | 1 |
| Irving, D | 1 |
| Shannak, K | 1 |
| Deck, JH | 1 |
| Wesemann, W | 1 |
| Kienzl, E | 1 |
| Eichinger, K | 1 |
| Olanow, CW | 1 |
| Gauger, LL | 1 |
| Cedarbaum, JM | 1 |
| Jolicoeur, FB | 1 |
| Rivest, R | 1 |
| Drumheller, A | 1 |
| Prell, GD | 1 |
| Khandelwal, JK | 1 |
| Blandina, P | 1 |
| Morrishow, AM | 1 |
| Green, JP | 1 |
| Date, I | 1 |
| Felten, DL | 1 |
| Felten, SY | 1 |
| Harnois, C | 1 |
| Di Paolo, T | 1 |
| Fazzini, E | 1 |
| Davoudi, H | 3 |
| Wolfe, N | 1 |
| Katz, DI | 1 |
| Almozlino, A | 1 |
| Smith, MC | 1 |
| Ahlskog, JE | 2 |
| Kelly, PJ | 2 |
| van Heerden, JA | 2 |
| Stoddard, SL | 2 |
| Tyce, GM | 4 |
| Windebank, AJ | 1 |
| Bailey, PA | 1 |
| Bell, GN | 1 |
| Blexrud, MD | 1 |
| Carmichael, SW | 2 |
| Dousa, MK | 1 |
| Conte-Devolx, B | 1 |
| Grino, M | 1 |
| Castanas, E | 1 |
| Guillaume, V | 1 |
| Tonon, MC | 1 |
| Vaudry, H | 1 |
| Oliver, C | 1 |
| Nakamura, S | 1 |
| Frantz, A | 1 |
| Dyrenfurth, I | 1 |
| Dennis, T | 2 |
| L'Heureux, R | 2 |
| Monfort, JC | 1 |
| Duyckaerts, C | 1 |
| Jolkkonen, J | 1 |
| Soininen, H | 1 |
| Halonen, T | 1 |
| Ylinen, A | 1 |
| Laulumaa, V | 1 |
| Laakso, M | 1 |
| Riekkinen, P | 2 |
| Sano, M | 2 |
| Andersen, K | 1 |
| Balldin, J | 1 |
| Gottfries, CG | 2 |
| Modigh, K | 1 |
| Svennerholm, L | 1 |
| Wallin, A | 1 |
| Thal, LJ | 1 |
| Nishi, K | 1 |
| Takubo, H | 1 |
| Muramoto, S | 1 |
| Araki, H | 1 |
| Jankovic, J | 1 |
| Grossman, R | 1 |
| Goodman, C | 1 |
| Pirozzolo, F | 1 |
| Schneider, L | 1 |
| Zhu, Z | 1 |
| Scardino, P | 1 |
| Garber, AJ | 1 |
| Jhingran, SG | 1 |
| Martin, S | 1 |
| Broseta, J | 1 |
| Diaz-Cascajo, P | 1 |
| García-March, G | 1 |
| Sánchez-Ledesma, MJ | 1 |
| Dissing, IC | 1 |
| Güttler, F | 1 |
| Pakkenberg, H | 2 |
| Lou, H | 1 |
| Gerdes, AM | 1 |
| Lykkelund, C | 1 |
| Rasmussen, V | 1 |
| Kraus, P | 1 |
| Backlund, EO | 1 |
| Granberg, PO | 1 |
| Hamberger, B | 1 |
| Knutsson, E | 1 |
| Mårtensson, A | 1 |
| Sedvall, G | 1 |
| Seiger, A | 1 |
| Olson, L | 1 |
| Stahl, SM | 1 |
| Faull, KF | 1 |
| Barchas, JD | 1 |
| Berger, PA | 1 |
| Gibson, CJ | 1 |
| Collins, MA | 1 |
| Neafsey, EJ | 1 |
| Birkmayer, W | 1 |
| Birkmayer, GJ | 1 |
| Vrecko, K | 1 |
| Mlekusch, W | 1 |
| Paletta, B | 1 |
| Ott, E | 1 |
| Szabo, G | 1 |
| Feldman, RG | 1 |
| Shigetomi, S | 1 |
| Chritton, SL | 1 |
| Yaksh, TL | 1 |
| Marquis, JK | 2 |
| Sladek, JR | 1 |
| Collier, TJ | 1 |
| Haber, SN | 1 |
| Deutch, AY | 2 |
| Redmond, DE | 1 |
| Goldstein, M | 1 |
| Lieberman, AN | 1 |
| Helmer, E | 1 |
| Koslow, M | 1 |
| Ransohoff, J | 1 |
| Kurlan, R | 1 |
| Goldblatt, D | 1 |
| Zaczek, R | 1 |
| Jeffries, K | 1 |
| Irvine, C | 1 |
| Coyle, J | 1 |
| Zubenko, GS | 1 |
| Nixon, RA | 1 |
| Youngster, SK | 1 |
| Sonsalla, PK | 1 |
| Sershen, H | 1 |
| Hashim, A | 1 |
| Lajtha, A | 1 |
| Harvey, NS | 1 |
| García de Yébenes, J | 1 |
| Bazán, E | 1 |
| Muradas, V | 2 |
| Reiriz, J | 1 |
| Romero, J | 1 |
| González-Elipe, J | 1 |
| Cash, R | 1 |
| Raisman, R | 1 |
| Portin, R | 1 |
| Globus, M | 1 |
| Rosenthal, J | 1 |
| Uzzan, A | 1 |
| Rainero, I | 1 |
| Pinessi, L | 1 |
| Riccio, A | 1 |
| Bergamasco, B | 1 |
| Cantello, R | 1 |
| Sandyk, R | 1 |
| Snider, SR | 1 |
| Bermejo Pareja, F | 1 |
| Martinez-Martin, P | 1 |
| van Praag, HM | 2 |
| Minderhoud, JM | 1 |
| Coppen, A | 1 |
| Metcalfe, M | 1 |
| Carroll, JD | 1 |
| Morris, JG | 1 |
| Sandler, M | 1 |
| Ruthven, CR | 1 |
| Goodwin, BL | 1 |
| Hunter, KR | 1 |
| Stern, GM | 1 |
| Ng, LK | 3 |
| Garelis, E | 2 |
| Sourkes, TL | 2 |
| Gordon, EK | 1 |
| Young, SN | 1 |
| Lal, S | 1 |
| Curzon, G | 3 |
| Paddison, RM | 1 |
| Griffith, RP | 1 |
| Laaksonen, H | 1 |
| Dinapoli, RP | 1 |
| Miachon, S | 1 |
| Dalmaz, Y | 1 |
| Schut, D | 1 |
| Nienhuis, RJ | 1 |
| Sweet, RD | 1 |
| McDowell, FH | 1 |
| West, KA | 1 |
| Roos, BE | 4 |
| Barbeau, A | 1 |
| Dowson, JH | 1 |
| Ahmed, R | 1 |
| Chow, R | 1 |
| Gillingham, FJ | 1 |
| Buscaino, GA | 1 |
| Sori, A | 1 |
| Casacchia, M | 1 |
| Reitano, M | 1 |
| Zamponi, A | 1 |
| Jones, DG | 1 |
| Robertson, MA | 1 |
| Cox, B | 1 |
| Danta, G | 1 |
| Schnieden, H | 1 |
| Yuill, GM | 1 |
| Mones, RJ | 1 |
| Gumpert, J | 1 |
| Sharpe, D | 1 |
| Sharpe, JA | 1 |
| Rewcastle, NB | 1 |
| Hill, M | 1 |
| Tasker, RR | 1 |
| Mrochek, JE | 1 |
| Dinsmore, SR | 1 |
| Ohrt, DW | 1 |
| Messiha, FS | 1 |
| Turek, I | 1 |
| Dziedzic, SW | 2 |
| Dziedzic, LB | 1 |
| Gitlow, SE | 2 |
| Adriaenssens, K | 1 |
| Mars, H | 2 |
| Molnár, G | 1 |
| Fodor, A | 1 |
| Voto Bernales, J | 1 |
| Cruz, GA | 1 |
| Davila, E | 1 |
| Bohuon, C | 1 |
| Woods, AC | 1 |
| Glaubiger, GA | 1 |
| Parkes, JD | 1 |
| Rees, JE | 1 |
| Kantamaneni, BD | 1 |
| Knill-Jones, R | 1 |
| Akbar, A | 1 |
| Das, S | 1 |
| Kataria, M | 1 |
| Kjällquist, A | 1 |
| Pontén, U | 1 |
| Sundbärg, G | 1 |
| Lycke, E | 1 |
| Magnusson, T | 1 |
| Svanborg, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effects of Supplementing Tyrosine on Blood Pressure in Parkinson's Disease[NCT01676103] | Phase 1/Phase 2 | 40 participants (Actual) | Interventional | 2012-09-30 | Completed | ||
| Repetitive Transcranial Magnetic Stimulation (rTMS) for Motor and Mood Symptoms of Parkinson's Disease (MASTER-PD), a Multicenter Clinical Trial[NCT01080794] | 61 participants (Actual) | Interventional | 2010-05-31 | Completed | |||
| Phase IIb Study of Intranasal Glutathione in Parkinson's Disease[NCT02424708] | Phase 2 | 45 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
To establish the safety and tolerability of rTMS in Parkinson's Disease. (NCT01080794)
Timeframe: Baseline through Month 6
| Intervention | incidents of an adverse event (Number) |
|---|---|
| Double rTMS | 18 |
| M1 Active rTMS + DLPFC Sham rTMS | 14 |
| DLPFC Active rTMS + M1 Sham rTMS | 1 |
| Double Sham rTMS | 1 |
To evaluate apathy in Parkinson's Disease. The AES mean scores were reported for each group at each time point. The AES Score Range is 0-42, where higher the score indicates greater severity of the apathy symptoms. (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline (Pre-Treatment) | Week 1 Post Treatment | Month 1 Post Treatment | Month 3 Post Treatment | Month 6 Post Treatment | |
| DLPFC Active rTMS + M1 Sham rTMS | 18.7 | 18.1 | 19.0 | 19.3 | 15.8 |
| Double rTMS | 15.6 | 16.2 | 17 | 16.9 | 17.8 |
| Double Sham rTMS | 16.3 | 15.5 | 15.0 | 16.1 | 16.2 |
| M1 Active rTMS + DLPFC Sham rTMS | 15.9 | 16.9 | 14.6 | 15.1 | 12.4 |
To assess mood symptoms in Parkinson's Disease. The BDI-II mean scores were reported for each group at each time point. The BDI-II Score Range is 0 - 63, where higher the score indicates greater severity of the mood symptoms. (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline (Pre-Treatment) | Week 1 Post Treatment | Month 1 Post Treatment | Month 3 Post Treatment | Month 6 Post Treatment | |
| DLPFC Active rTMS + M1 Sham rTMS | 21.7 | 18.2 | 20.2 | 19.0 | 15.7 |
| Double rTMS | 23.2 | 20.7 | 16.4 | 17.9 | 20.1 |
| Double Sham rTMS | 18.8 | 13.7 | 13.1 | 14.7 | 16.8 |
| M1 Active rTMS + DLPFC Sham rTMS | 18.5 | 16.5 | 16.7 | 19.1 | 16.3 |
To evaluate anxiety in Parkinson's Disease. The CAS mean scores were reported for each group at each time point. The CAS Score Range is 0 - 100, where higher the score indicates greater severity of the anxiety symptoms. (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline (Pre-Treatment) | Week 1 Post Treatment | Month 1 Post Treatment | Month 3 Post Treatment | Month 6 Post Treatment | |
| DLPFC Active rTMS + M1 Sham rTMS | 33.4 | 27.6 | 30.8 | 31.4 | 24.8 |
| Double rTMS | 36.3 | 34.2 | 31.7 | 33.1 | 33.4 |
| Double Sham rTMS | 37.5 | 32.4 | 28.2 | 28.5 | 35.0 |
| M1 Active rTMS + DLPFC Sham rTMS | 34.3 | 31.0 | 30.8 | 27.3 | 28.1 |
To assess symptom severity and treatment response in Parkinson's Disease. The CGI mean scores were reported for each group at each time point. The CGI Score Range is 1 - 8, where higher the score indicates greater severity of illness or worsening of illness. (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.
| Intervention | units on a scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline (Pre-Treatment): Severity | Week 1 Post Treatment: Severity | Week 1 Post Treatment: Improvement | Month 1 Post Treatment: Severity | Month 1 Post Treatment: Improvement | Month 3 Post Treatment: Severity | Month 3 Post Treatment: Improvement | Month 6 Post Treatment: Severity | Month 6 Post Treatment: Improvement | |
| DLPFC Active rTMS + M1 Sham rTMS | 4.3 | 4.7 | 3.5 | 4.4 | 3.7 | 4.4 | 3.6 | 4.3 | 3.7 |
| Double rTMS | 4.9 | 4.8 | 3.6 | 4.4 | 3.5 | 4.6 | 3.7 | 4.2 | 3.5 |
| Double Sham rTMS | 3.6 | 3.9 | 3.0 | 4.1 | 3.5 | 4.4 | 3.6 | 4.6 | 3.4 |
| M1 Active rTMS + DLPFC Sham rTMS | 4.7 | 4.9 | 3.5 | 4.8 | 3.8 | 3.8 | 3.4 | 5.0 | 4.2 |
"To evaluate the depressive mood symptoms in PD.~The HAM-D mean scores were reported for each group at each time point. The HAM-D Score Range is 0 - 56, where higher the score indicates greater severity of depressive mood symptoms." (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline (Pre-Treatment) | Week 1 Post-Treatment | Month 1 Post-Treatment | Month 3 Post-Treatment | Month 6 Post-Treatment | |
| DLPFC Active rTMS + M1 Sham rTMS | 13.8 | 9.4 | 12.4 | 10.4 | 10.4 |
| Double rTMS | 15.2 | 11.3 | 10.6 | 10.7 | 10.4 |
| Double Sham rTMS | 14.1 | 9.3 | 8.0 | 11.1 | 10.4 |
| M1 Active rTMS + DLPFC Sham rTMS | 16.7 | 11.2 | 10.1 | 10.1 | 8.6 |
To screen and follow cognitive function in Parkinson's Disease. The MoCA mean scores were reported for each group at each time point. The MoCA Score Range is 0 - 30, where 26-30 indicates normal cognition. (NCT01080794)
Timeframe: pre-treatment; 0,1,3, and 6 months post-treatment
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline (Pre-Treatment) | Week 1 Post Treatment | Month 1 Post Treatment | Month 3 Post Treatment | Month 6 Post Treatment | |
| DLPFC Active rTMS + M1 Sham rTMS | 27.3 | 26.3 | 26.8 | 26.7 | 26.6 |
| Double rTMS | 28.2 | 26.8 | 28.8 | 26.5 | 28.0 |
| Double Sham rTMS | 26.2 | 27.8 | 28.7 | 24.9 | 28.0 |
| M1 Active rTMS + DLPFC Sham rTMS | 26.6 | 27.1 | 27.2 | 25.3 | 27.9 |
"To evaluate the motor symptoms in Parkinson's Disease.~The UPDRS-III mean scores were reported for each group at each time point. The UPDRS-III Score Range is 0 - 56, where higher the score indicates greater severity of the motor symptoms." (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline (Pre-Treatment) | Week 1 Post-Treatment | Month 1 Post-Treatment | Month 3 Post-Treatment | Month 6 Post-Treatment | |
| DLPFC Active rTMS + M1 Sham rTMS | 32.8 | 30.3 | 29.3 | 31.5 | 28.8 |
| Double rTMS | 32.3 | 31.2 | 30.1 | 29.6 | 30.5 |
| Double Sham rTMS | 28.9 | 28.2 | 28.6 | 28.6 | 29.0 |
| M1 Active rTMS + DLPFC Sham rTMS | 33.1 | 27.4 | 28.1 | 33.2 | 30.6 |
To assess the quality of life (QOL) in Parkinson's Disease. The PDQ-39 mean scores were reported for each group at each time point. The PDQ-39 Score Range is 0 - 156, where higher the score indicates greater impact on quality of life. (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline (Pre-Treatment) | Week 1 Post Treatment | Month 1 Post Treatment | Month 3 Post Treatment | Month 6 Post Treatment | |
| DLPFC Active rTMS + M1 Sham rTMS | 51.9 | 46.8 | 49.4 | 49.4 | 49 |
| Double rTMS | 57.6 | 51.2 | 49.9 | 51.7 | 50.5 |
| Double Sham rTMS | 55.5 | 43.1 | 40.9 | 43.1 | 47.5 |
| M1 Active rTMS + DLPFC Sham rTMS | 61.5 | 60.7 | 56.8 | 53.1 | 48.3 |
"To assess apathy, cognition, depression, activities of daily living (ADL), quality of life (QOL), and motor symptoms in Parkinson's Disease.~The UPDRS I, II, IV total mean scores were reported for each group at each time point. The UPDRS I, II, IV scores were added together for each patient, with a total score range of 0 - 91, where higher the score indicates greater severity of the symptoms." (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline (Pre-Treatment) | Week 1 Post Treatment | Month 1 Post Treatment | Month 3 Post Treatment | Month 6 Post Treatment | |
| DLPFC Active rTMS + M1 Sham rTMS | 21.5 | 19.3 | 19.9 | 18.9 | 20.2 |
| Double rTMS | 25.4 | 23.3 | 21.8 | 21.1 | 23.8 |
| Double Sham rTMS | 19.6 | 15.5 | 16.5 | 16.9 | 18.8 |
| M1 Active rTMS + DLPFC Sham rTMS | 26.1 | 23.2 | 23.0 | 23.2 | 22.7 |
19 reviews available for homovanillic acid and Parkinson Disease
| Article | Year |
|---|---|
Problems associated with fluid biomarkers for Parkinson's disease.
Topics: alpha-Synuclein; Amyloid beta-Peptides; Biomarkers; Homovanillic Acid; Humans; Hydroxyindoleacetic A | 2010 |
Recent advances in CSF biomarkers for Parkinson's disease.
Topics: Animals; Biomarkers; Dopamine; Homovanillic Acid; Humans; Mass Screening; Parkinson Disease | 2012 |
Behavioral manifestations of movement disorders. Parkinson's and Huntington's disease.
Topics: Adult; Aged; Dementia; Depression; Depressive Disorder; Homovanillic Acid; Humans; Huntington Diseas | 1984 |
Dopamine and depression: a review of recent evidence. I. Empirical studies.
Topics: Amphetamine; Antipsychotic Agents; Brain; Bromocriptine; Depressive Disorder; Dihydroxyphenylalanine | 1983 |
[Biochemical bases of Parkinson disease].
Topics: Acetylcholine; Amantadine; Aromatic Amino Acid Decarboxylase Inhibitors; Brain; Dopa Decarboxylase; | 1984 |
Early onset Parkinson's disease: are juvenile- and young-onset different?
Topics: Adolescent; Adult; Autonomic Nervous System; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic | 1994 |
Presymptomatic detection of Parkinson's disease.
Topics: Autopsy; Biomarkers; Brain; Dopamine; Homovanillic Acid; Humans; NAD(P)H Dehydrogenase (Quinone); Or | 1993 |
L-threo-DOPS in advanced parkinsonism.
Topics: Brain; Cyclic AMP; Droxidopa; Homovanillic Acid; Humans; Neurologic Examination; Norepinephrine; Par | 1993 |
[Modulation of dopaminergic receptor sensitivity in the central nervous system: important parameters in synaptic function regulation].
Topics: Acetylcholine; Adenylyl Cyclases; Animals; Antipsychotic Agents; Apomorphine; Behavior; Corpus Stria | 1979 |
Catecholamines and neurologic diseases (second of two parts).
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Brain; Brain Diseases; Catecholamines; Cereb | 1975 |
Amine precursors in neurologic disorders and the psychoses.
Topics: Acetylcholine; Corpus Striatum; Dopamine; Homovanillic Acid; Humans; Huntington Disease; Hydroxyindo | 1975 |
Clinical pharmacokinetics of levodopa in parkinson's disease.
Topics: Carboxy-Lyases; Cardiovascular Diseases; Dopamine; Dose-Response Relationship, Drug; Dyskinesia, Dru | 1976 |
The striopallidal system: Its implication in motor disorders.
Topics: Animals; Basal Ganglia Diseases; Cats; Corpus Striatum; Disease Models, Animal; Dopamine; Extrapyram | 1975 |
Psychiatric disorders in parkinsonism. 1. Functional illnesses and personality.
Topics: Antidepressive Agents; Clozapine; Depressive Disorder; Dopamine; Electroconvulsive Therapy; Female; | 1986 |
Parkinson's disease: from brain homogenate to treatment.
Topics: Animals; Brain; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; Dopa Decarboxylase; Dopami | 1973 |
Monoamine metabolites in lumbar CSF: the question of their origin in relation to clinical studies.
Topics: Animals; Biological Transport, Active; Brain; Cats; Cerebral Ventricles; Cerebrospinal Fluid; Choroi | 1974 |
Serotonergic mechanisms and extrapyramidal function in man.
Topics: 5-Hydroxytryptophan; Carbidopa; Cerebellar Diseases; Creutzfeldt-Jakob Syndrome; Down Syndrome; Extr | 1974 |
Dopamine in the basal ganglia. Its role and therapeutic implications (including the clinical use of L-DOPA).
Topics: Amphetamine; Animals; Basal Ganglia; Brain Chemistry; Butyrophenones; Corpus Striatum; Dihydroxyphen | 1973 |
[Biochemical and clinical correlations in Parkinson's disease].
Topics: Brain; Dihydroxyphenylalanine; Dopamine; Homovanillic Acid; Humans; Movement Disorders; Norepinephri | 1972 |
22 trials available for homovanillic acid and Parkinson Disease
| Article | Year |
|---|---|
Pharmacokinetics and pharmacodynamics of a single dose Nilotinib in individuals with Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Aged; Aged, 80 and over; alpha-Synuclein; Biomarkers; Brain; | 2019 |
Parkinson's disease: the effect of L-dopa therapy on urinary free catecholamines and metabolites.
Topics: Adolescent; Adult; Aged; Antiparkinson Agents; Catecholamines; Creatinine; Dopamine; Female; Homovan | 2007 |
Deprenyl in Parkinson disease.
Topics: Adult; Aged; Carbidopa; Dopamine; Double-Blind Method; Drug Combinations; Epinephrine; Homovanillic | 1981 |
Cerebrospinal fluid homovanillic acid in the DATATOP study on Parkinson's disease. Parkinson Study Group.
Topics: Adult; Aged; Drug Therapy, Combination; Female; Homovanillic Acid; Humans; Male; Middle Aged; Parkin | 1995 |
Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease.
Topics: Aged; Blood Pressure; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Hemodynamics; H | 1993 |
Human transplacental transfer of carbidopa/levodopa.
Topics: Antiparkinson Agents; Carbidopa; Dopamine; Female; Fetus; Homovanillic Acid; Humans; Levodopa; Mater | 1995 |
Effect of one month's treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients.
Topics: Aged; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Catechols; Dopamine Agents; Dou | 1996 |
The metabolism of L-DOPA and L-threo-3,4-dihydroxyphenylserine and their effects on monoamines in the human brain: analysis of the intraventricular fluid from parkinsonian patients.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Antiparkinson Agents; Biogenic Monoamines; Cerebral Ventricle | 1996 |
Increase in salsolinol level in the cerebrospinal fluid of parkinsonian patients is related to dementia: advantage of a new high-performance liquid chromatography methodology.
Topics: Adult; Aged; Antiparkinson Agents; Chromatography, High Pressure Liquid; Dementia; Female; Homovanil | 1997 |
Plasma HVA levels following debrisoquine administration do not reflect cerebral dopamine loss in early Parkinson's disease.
Topics: Adult; Aged; Biomarkers; Cerebral Cortex; Debrisoquin; Dopamine; Female; Homovanillic Acid; Humans; | 1994 |
Nigrostriatal dopaminergic activities in dementia with Lewy bodies in relation to neuroleptic sensitivity: comparisons with Parkinson's disease.
Topics: Adult; Antipsychotic Agents; Autoradiography; Brain; Brain Chemistry; Cell Count; Dopamine; Female; | 1998 |
Therapeutic effect and mechanism of repetitive transcranial magnetic stimulation in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Biogenic Monoamines; Electromagnetic Fields; Female; gamma-Aminobutyric Aci | 2001 |
[Effect of MK-486 alone on Parkinsonism; studies on the clinical symptoms and catecholamine concentrations in the blood, urine and cerebrospinal fluid].
Topics: Aged; Carbidopa; Catecholamines; Clinical Trials as Topic; Dihydroxyphenylalanine; Dopamine; Female; | 1977 |
Clinical and pharmacological evaluation of the effects of piribedil in patients with parkinsonism.
Topics: Aged; Antiparkinson Agents; Chorea; Clinical Trials as Topic; Confusion; Dioxoles; Dopamine; Drug Ev | 1975 |
Dopaminergic agonist effects on Parkinsonian clinical features and brain monamine metabolism.
Topics: Aged; Brain; Clinical Trials as Topic; Dopamine; Drug Evaluation; Drug Therapy, Combination; Female; | 1975 |
Conjugation of L-DOPA and its metabolites after oral and intravenous administration to Parkinsonian patients.
Topics: 3,4-Dihydroxyphenylacetic Acid; Administration, Oral; Aged; Clinical Trials as Topic; Dopamine; Dose | 1975 |
Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with Parkinson's disease.
Topics: Activities of Daily Living; Adult; Antiparkinson Agents; Caudate Nucleus; Cryopreservation; Cyclospo | 1992 |
A double-blind evaluation of electroconvulsive therapy in Parkinson's disease with "on-off" phenomena.
Topics: Aged; Clinical Trials as Topic; Double-Blind Method; Electroconvulsive Therapy; Female; Homovanillic | 1987 |
Tetrahydrobiopterin and Parkinson's disease.
Topics: Adult; Antiparkinson Agents; Benserazide; Biopterins; Clinical Trials as Topic; Drug Combinations; H | 1989 |
Transplantation of adrenal medullary tissue to striatum in parkinsonism. First clinical trials.
Topics: Adrenal Medulla; Caudate Nucleus; Clinical Trials as Topic; Corpus Striatum; Female; Homovanillic Ac | 1985 |
Levodopa and L-tryptophan therapy in Parkinsonism.
Topics: Aged; Depression; Dihydroxyphenylalanine; Female; Gait; Homovanillic Acid; Humans; Hydroxyindoleacet | 1972 |
Parkinson disease treated with a suspected dopamine receptor agonist.
Topics: Adult; Aged; Amantadine; Aromatic Amino Acid Decarboxylase Inhibitors; Benztropine; Dihydroxyphenyla | 1974 |
292 other studies available for homovanillic acid and Parkinson Disease
| Article | Year |
|---|---|
AJ76 and UH232 as potential agents for diagnosing early-stage Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Dopamine; Dopamine Antagonists; Haloperidol; Homovanillic A | 2023 |
Correlations between cerebrospinal fluid homovanillic acid and dopamine transporter SPECT in degenerative parkinsonian syndromes.
Topics: Dopamine; Dopamine Plasma Membrane Transport Proteins; Homovanillic Acid; Humans; Parkinson Disease; | 2023 |
Serotonin and dopamine depletion in distinct brain regions may cause anxiety in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice as a model of early Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anxiety; Corpus Striatum; Disease Models, Ani | 2023 |
Differential abnormalities of cerebrospinal fluid dopaminergic versus noradrenergic indices in synucleinopathies.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Cohort Studies; Dopamine; Dopaminergic Neurons; Female; Homova | 2021 |
Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Homovanillic Acid; Humans; Levodopa; Neurotransmitter Agents; Parkin | 2021 |
Preliminary Analysis of Parkinson-like Motor Coordination Abnormityin Brain-specific hS100B Transgenic Mice.
Topics: Animals; Brain; Disease Models, Animal; Dopamine; G-Protein-Coupled Receptor Kinase 2; Homovanillic | 2017 |
Zonisamide inhibits monoamine oxidase and enhances motor performance and social activity.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Astrocytes; Brain; Dopamine; Explorat | 2017 |
Monoaminergic Markers Across the Cognitive Spectrum of Lewy Body Disease.
Topics: Aged; Biogenic Monoamines; Biomarkers; Cognition Disorders; Cognitive Dysfunction; Diagnosis, Differ | 2018 |
Neuroprotective effect of the carnosine - α-lipoic acid nanomicellar complex in a model of early-stage Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antioxidants; Brain; Carnosine; Dopamine; Homovanillic Acid | 2018 |
Therapeutic efficacy of regulable GDNF expression for Huntington's and Parkinson's disease by a high-induction, background-free "GeneSwitch" vector.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Disease Models, Animal; Gene Expression | 2018 |
Octanoic acid prevents reduction of striatal dopamine in the MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Caprylates; C | 2018 |
GABAA-receptor activation in the subthalamic nucleus compensates behavioral asymmetries in the hemiparkinsonian rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Amphetamine; Animals; Disease Models, Animal; Diz | 2013 |
Neuroprotective effect of hydroxysafflor yellow A on 6-hydroxydopamine-induced Parkinson's disease in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Behavior, Animal; Chalcone; Gene Expression Re | 2013 |
Levels of HVA, 5-HIAA, and MHPG in the CSF of vascular parkinsonism compared to Parkinson's disease and controls.
Topics: Aged; Cerebrovascular Disorders; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Male; | 2013 |
The subthalamic activity and striatal monoamine are modulated by subthalamic stimulation.
Topics: 3,4-Dihydroxyphenylacetic Acid; Action Potentials; Animals; Biogenic Monoamines; Chromatography, Hig | 2014 |
Ontogenetic manganese exposure with perinatal 6-OHDA lesioning alters behavioral responses of rats to dopamine D₁ and D2 agonist treatments.
Topics: Animals; Behavior, Animal; Desipramine; Dopamine; Dopamine Agonists; Exploratory Behavior; Female; H | 2014 |
Assessment of the role of multidrug resistance-associated proteins in MPTP neurotoxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Allopurinol; Animals; | 2013 |
Protective effect of chinonin in MPTP-induced C57BL/6 mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat | 2014 |
Is Parkinson's disease a vesicular dopamine storage disorder? Evidence from a study in isolated synaptic vesicles of human and nonhuman primate striatum.
Topics: Aged; Aged, 80 and over; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Uptake | 2014 |
A potential target for the treatment of Parkinson's disease: effect of lateral habenula lesions.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Apomorphine; Corpus Striatum; Disease Mo | 2014 |
Progressive nigrostriatal terminal dysfunction and degeneration in the engrailed1 heterozygous mouse model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Autophagy; Corpus Striatum; Disease Models, Animal; Disease | 2015 |
Endometrial stem cell transplantation in MPTP- exposed primates: an alternative cell source for treatment of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Count; Cell Movement; Endometrium; Femal | 2015 |
AAV.shRNA-mediated downregulation of ROCK2 attenuates degeneration of dopaminergic neurons in toxin-induced models of Parkinson's disease in vitro and in vivo.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Dependovirus; Disease Models, Animal; Do | 2015 |
Decreased behavioral response to intranigrally administered GABAA agonist muscimol in the lactacystin model of Parkinson's disease may result from partial lesion of nigral non-dopamine neurons: comparison to the classical neurotoxin 6-OHDA.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcysteine; Animals; Cell Count; Corpus Striatum; Dopamine; Dose | 2015 |
Apocyanin, a Microglial NADPH Oxidase Inhibitor Prevents Dopaminergic Neuronal Degeneration in Lipopolysaccharide-Induced Parkinson's Disease Model.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetophenones; Animals; Cytokines; Disease Models, Animal; Dopaminer | 2016 |
Subthalamic Nucleus Deep Brain Stimulation Modulate Catecholamine Levels with Significant Relations to Clinical Outcome after Surgery in Patients with Parkinson's Disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Antiparkinson Agents; Area Under Curve; Catecholamines; Deep B | 2015 |
Ursolic acid attenuates oxidative stress in nigrostriatal tissue and improves neurobehavioral activity in MPTP-induced Parkinsonian mouse model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Ani | 2016 |
Homovanillic acid in CSF of mild stage Parkinson's disease patients correlates with motor impairment.
Topics: Aged; Antiparkinson Agents; Biomarkers; Disease Progression; Female; Homovanillic Acid; Humans; Levo | 2017 |
Cerebrospinal fluid levels of catecholamines and its metabolites in Parkinson's disease: effect of l-DOPA treatment and changes in levodopa-induced dyskinesia.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Aged; Aging; Antiparkinson Agents; Catecholamines; Dopamine; | 2017 |
[Effect and mechanism on dopamine contents of striatum in rat model of Parkinson's disease ginsenoside Rg1].
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Central Nervous System Agents; Corpus Str | 2008 |
Correlation between changes in CSF dopamine turnover and development of dyskinesia in Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Age of Onset; Aged; Disease Progression; Dopamine; Dyskinesias; Homo | 2009 |
A novel anti-Parkinsonian agent, zonisamide, attenuates MPTP-induced neurotoxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anticonvulsants; Antiparkinson Agents; Astroc | 2009 |
Monoamines, BDNF, IL-6 and corticosterone in CSF in patients with Parkinson's disease and major depression.
Topics: Aged; Analysis of Variance; Biogenic Monoamines; Brain-Derived Neurotrophic Factor; Corticosterone; | 2010 |
Cerebrospinal fluid metabolite and nigrostriatal dopaminergic function in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Basal Ganglia; Dopamine; Dopamine Plasma Membrane Transport Proteins; Femal | 2010 |
Inflammation and age-related iron accumulation in F344 rats.
Topics: Age Factors; Aging; Animals; Dopamine; Endotoxins; Ferritins; Homovanillic Acid; Inflammation; Iron; | 2008 |
On the role of P2X(7) receptors in dopamine nerve cell degeneration in a rat model of Parkinson's disease: studies with the P2X(7) receptor antagonist A-438079.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Analysis of Variance; Animals; Brain; Cell Count; | 2010 |
Modeling a sensitization stage and a precipitation stage for Parkinson's disease using prenatal and postnatal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Aging; Animals; Birth | 2010 |
Modeling Parkinson's disease genetics: altered function of the dopamine system in Adh4 knockout mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Alcohol Dehydrogenase; Amphetamine; Analysis of Variance; Animals; A | 2011 |
S100B transgenic mice develop features of Parkinson's disease.
Topics: Animals; Brain; Dopamine; G-Protein-Coupled Receptor Kinase 2; G-Protein-Coupled Receptor Kinase 5; | 2011 |
CSF xanthine, homovanillic acid, and their ratio as biomarkers of Parkinson's disease.
Topics: Adult; Age of Onset; Antiparkinson Agents; Biomarkers; Chromatography, High Pressure Liquid; Female; | 2011 |
Adh1 and Adh1/4 knockout mice as possible rodent models for presymptomatic Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Alcohol Dehydrogenase; Analysis of Variance; Animals; Apomorphine; C | 2012 |
Contralateral retinal dopamine decrease and melatonin increase in progression of hemiparkinsonium rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Chromatography, High Pressure Liquid; Disease Progression; | 2012 |
Protective effect of extract of Acanthopanax senticosus Harms on dopaminergic neurons in Parkinson's disease mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Brain; Caspase 3; Chromatog | 2012 |
Pegylated granulocyte colony-stimulating factor conveys long-term neuroprotection and improves functional outcome in a model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Chroma | 2012 |
Possible sporadic rapid-onset dystonia-parkinsonism.
Topics: Adult; Dopamine; Dystonic Disorders; Female; Homovanillic Acid; Humans; Parkinson Disease; Time Fact | 2002 |
Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat.
Topics: 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Animals; Biomarkers; Dopamine; Environm | 2002 |
Assessment of CSF homovanillic acid levels distinguishes dementia with Lewy bodies from Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Diagnosis, Differential; Female; Homovanillic Acid; Humans; Lewy Body Disea | 2002 |
Developmental exposure to the pesticides paraquat and maneb and the Parkinson's disease phenotype.
Topics: Aging; Animals; Animals, Newborn; Body Weight; Cell Count; Chromatography, High Pressure Liquid; Dop | 2002 |
Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Blotting, Wes | 2003 |
[Pseudopheochromocytoma in Parkinson disease and depression].
Topics: Adrenal Gland Neoplasms; Antidepressive Agents; Antiparkinson Agents; Catecholamines; Depressive Dis | 2003 |
3,4-Dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: implications for Parkinson's disease pathogenesis.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Disease Models, Animal; Dopamine; Dose-Response Relationshi | 2003 |
Behavioral and neurochemical effects of noradrenergic depletions with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine in 6-hydroxydopamine-induced rat model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Amphetamine; Analysis of Variance; Animals; Basal | 2004 |
Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Behavior, Animal; Brain; Brocresine; | 2004 |
Cerebrospinal fluid analysis differentiates multiple system atrophy from Parkinson's disease.
Topics: Adult; Aged; Benzamides; Brain; Diagnosis, Differential; Electromyography; Enzyme-Linked Immunosorbe | 2004 |
Infantile Parkinsonism-dystonia and elevated dopamine metabolites in CSF.
Topics: Dopamine; Dystonic Disorders; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Infant, N | 2004 |
Novel dopamine releasing response of an anti-convulsant agent with possible anti-Parkinson's activity.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Antiparkinson Agents; Behavior, Animal; | 2004 |
Inhibition of brain mitochondrial respiration by dopamine and its metabolites: implications for Parkinson's disease and catecholamine-associated diseases.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Chemistry; Catecholamines; Cell Respiration; Dopamine | 2004 |
Pramipexole has ameliorating effects on levodopa-induced abnormal dopamine turnover in parkinsonian striatum and quenching effects on dopamine-semiquinone generated in vitro.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Antiparkinson Agents; Benzoquinones; | 2005 |
Neuroprotective properties of the natural phenolic antioxidants curcumin and naringenin but not quercetin and fisetin in a 6-OHDA model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antioxidants; Curcumin; Disease Models, Animal; Dopamine; F | 2005 |
Parkin suppresses the expression of monoamine oxidases.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; B-Lymphocytes; Binding Sites; Cell Line, Transformed; Cell | 2006 |
Further validation of the corridor task for assessing deficit and recovery in the hemi-Parkinsonian rat: restoration of bilateral food retrieval by dopamine receptor agonism.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Behavior, Animal; Brain Chemistry; Chromatogra | 2006 |
Proteasome inhibitor model of Parkinson's disease in mice is confounded by neurotoxicity of the ethanol vehicle.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Central Nervous System Depressants; Chromatography, High Pr | 2007 |
Long-term survival of encapsulated GDNF secreting cells implanted within the striatum of parkinsonized rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Cell Line; Cell Survival; Corpus Striatum | 2007 |
Circadian rhythm of CSF monoamines and hypocretin-1 in restless legs syndrome and Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Biogenic Monoamines; Chromatography, High Pressure Liquid; Cir | 2009 |
Serotonergic neurones are not involved in action of L-dopa in Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Stem; Disease Models, Animal; Dopa Decarboxylase; Dop | 1980 |
[Neurochemical aspects of parkinsonism. Review of the literature].
Topics: Acetylcholine; Amino Acids; Corpus Striatum; Dopamine; Homovanillic Acid; Humans; Norepinephrine; Pa | 1982 |
A neuropharmacological and neuroendocrine study on idiopathic and chronic pharmacological Parkinsonism.
Topics: Adult; Aged; Antipsychotic Agents; Chronic Disease; Circadian Rhythm; Homovanillic Acid; Humans; Hyd | 1980 |
Biogenic amine disturbances in cerebrospinal fluid in parkinsonism and unipolar depression: use of the probenecid method.
Topics: Aged; Dementia; Depressive Disorder; Dopamine; Female; Homovanillic Acid; Humans; Hydroxyindoleaceti | 1981 |
Serotonin and dopamine disturbances in patients with unipolar depression and Parkinsonism.
Topics: Brain; Depressive Disorder; Dopamine; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; M | 1981 |
Effects of oral L-tyrosine administration on CSF tyrosine and homovanillic acid levels in patients with Parkinson's disease.
Topics: Administration, Oral; Chromatography, High Pressure Liquid; Homovanillic Acid; Humans; Hydroxyindole | 1982 |
Urinary noradrenaline and serotonin metabolites in drug-free Parkinson patients and the effect of L-dopa treatment.
Topics: Aged; Cyclic AMP; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Levodopa; Male; Metho | 1982 |
A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Brain Chemistry; Disease Models, Anima | 1983 |
Analysis of neurotransmitter metabolites and adenosine 3',5'-monophosphate in the CSF of patients with extrapyramidal motor disorders.
Topics: Adult; Basal Ganglia Diseases; Cyclic AMP; Female; Homovanillic Acid; Humans; Huntington Disease; Hy | 1984 |
Methionine-enkephalin, substance P, and homovanillic acid in the CSF of parkinsonian patients.
Topics: Adult; Aged; Dopamine; Enkephalin, Methionine; Female; Homovanillic Acid; Humans; Male; Middle Aged; | 1984 |
Altered serotonin metabolism in depressed patients with parkinson's disease.
Topics: Aged; Depression; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Male; Methoxyhydroxyp | 1984 |
Monoamine metabolites in human cerebrospinal fluid. HPLC/ED method.
Topics: 3,4-Dihydroxyphenylacetic Acid; Alzheimer Disease; Chromatography, High Pressure Liquid; Depression; | 1984 |
Reaction time and vigilance in Parkinson's disease. Possible role of altered norepinephrine metabolism.
Topics: Aged; Arousal; Glycols; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Methoxyhydroxyphenylgly | 1984 |
Tyrosine administration increases striatal dopamine release in rats with partial nigrostriatal lesions.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Homovani | 1980 |
Urinary homovanillic acid and c-AMP in drug-free Parkinson patients: effect of L-dopa treatment.
Topics: Aged; Carbidopa; Cyclic AMP; Drug Combinations; Female; Homovanillic Acid; Humans; Levodopa; Male; M | 1981 |
[Approaches to the study of dopamine metabolism in various extrapyramidal diseases].
Topics: Athetosis; Basal Ganglia Diseases; Chorea; Dopamine; Dystonia Musculorum Deformans; Homovanillic Aci | 1981 |
Parkinson's disease. The possible relationship of laterality to dementia and neurochemical findings.
Topics: Acetylcholinesterase; Aged; Alzheimer Disease; Cognition; Dementia; Functional Laterality; Homovanil | 1984 |
Central catecholamine metabolism in vivo and the cognitive and motor deficits in Parkinson's disease.
Topics: Blood Platelets; Cognition; Glycols; Homovanillic Acid; Humans; Male; Methoxyhydroxyphenylglycol; Mi | 1983 |
[3H]spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy.
Topics: Aged; Brain; Butyrophenones; Caudate Nucleus; Dopamine; Homovanillic Acid; Humans; Levodopa; Nucleus | 1984 |
[Madopar in the treatment of paralysis agitans: II. TRH activation test, EMG examination and HVA level in cerebrospinal fluid before and after treatment].
Topics: Aged; Benserazide; Drug Combinations; Electromyography; Female; Homovanillic Acid; Humans; Hydrazine | 1980 |
Homovanillic acid in the cerebrospinal fluid of Parkinsonian patients.
Topics: Female; Homovanillic Acid; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenylacetates; P | 1983 |
3-O-methyldopa blocks dopa metabolism in rat corpus striatum.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug | 1982 |
Imbalance of brain monoamines and clinical disorders.
Topics: Biogenic Amines; Brain; Depressive Disorder; Dopamine; Homovanillic Acid; Humans; Nervous System Dis | 1982 |
Dopamine deficiency in the cerebral cortex in Parkinson disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Cerebral Cortex; Dopamine; Hippocampus; Homovanillic Acid; Hum | 1982 |
Normal plasma dopamine-beta-hydroxylase in non-treated and treated Parkinson patients.
Topics: Aged; Dopamine beta-Hydroxylase; Female; Homovanillic Acid; Humans; Levodopa; Male; Middle Aged; Par | 1981 |
Interference of levodopa and its metabolites with colorimetry of uric acid.
Topics: 3,4-Dihydroxyphenylacetic Acid; Colorimetry; Dopamine; Homovanillic Acid; Humans; Levodopa; Parkinso | 1981 |
A family with hereditary juvenile dystonia-parkinsonism.
Topics: Adult; Aged; Antiparkinson Agents; Chromosome Aberrations; Chromosome Disorders; Dystonia; Female; F | 1995 |
Effects of the catechol-O-methyltransferase inhibitor tolcapone in Parkinson's disease: correlations between concentrations of dopaminergic substances in the plasma and cerebrospinal fluid and clinical improvement.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Antiparkinson Agents; Benzophenones; Carbidopa; Catechol O-Met | 1995 |
Presence of N-methyl-norsalsolinol in the CSF: correlations with dopamine metabolites of patients with Parkinson's disease.
Topics: Adult; Aged; Cerebrospinal Fluid Proteins; Dopamine; Female; Homovanillic Acid; Humans; Isoquinoline | 1995 |
Markers of dopamine depletion and compensatory response in striatum and cerebrospinal fluid.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Biomarkers; Corpus Striatum; Dopamine; Homovanillic Acid; L | 1995 |
Complex deficits on reaction time performance following bilateral intrastriatal 6-OHDA infusion in the rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Frontal | 1995 |
Influence of selective inhibition of monoamine oxidase A or B on striatal metabolism of L-DOPA in hemiparkinsonian rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Clorgyline; Corpus Striatum; Dialysis; Dopamine; Homovanill | 1995 |
Visual and auditory evoked potentials in early onset Parkinson's disease and their relationship to cerebrospinal fluid monoamine metabolites.
Topics: Acoustic Stimulation; Adolescent; Adult; Aged; Evoked Potentials, Auditory, Brain Stem; Evoked Poten | 1993 |
Cerebrospinal dopamine metabolites in rats after intrastriatal administration of 6-hydroxydopamine or 1-methyl-4-phenylpyridinium ion.
Topics: 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dopamine; gam | 1995 |
Hereditary parkinsonism with multiple system degeneration: beneficial effect of anticholinergics, but not of levodopa.
Topics: Adult; Amantadine; Basal Ganglia; Carbidopa; Cerebellar Ataxia; Cholinergic Antagonists; Consanguini | 1994 |
Differences in nigral neuron number and sensitivity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57/bl and CD-1 mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Biomarkers; Calbindin 1; Calbindins; | 1994 |
Meige syndrome in the spectrum of Lewy body disease.
Topics: Biogenic Amines; Brain; Dopamine; Homovanillic Acid; Humans; Male; Meige Syndrome; Middle Aged; Park | 1994 |
Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Biopterins; Brain Diseases; Carbidopa; Corpus Striatum; Cyc | 1993 |
Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Brain Chemistry; Caudate Nucleus; Dopamine; Electron Transport | 1994 |
Assessment of the dopaminergic lesion in Parkinson's disease by CSF markers.
Topics: 3,4-Dihydroxyphenylacetic Acid; Brain; Dopamine; Homovanillic Acid; Humans; Levodopa; Neurons; Parki | 1993 |
Plasma levels of levodopa and its main metabolites in parkinsonian patients after conventional and controlled-release levodopa-carbidopa associations.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Antiparkinson Agents; Blood-Brain Barrier; Carbidopa; Delayed- | 1993 |
A clinical and pharmacokinetic case study of an interaction of levodopa and antituberculous therapy in Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Antitubercular Agents; Dopa Decarboxylase; Homovanillic Acid; Humans | 1995 |
Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cerebellum; Corpus Striatum; Dopamine; Dopamine Agents; Enz | 1996 |
Variable phenotype of rapid-onset dystonia-parkinsonism.
Topics: Adolescent; Adult; Dopamine; Dystonia; Female; Follow-Up Studies; Genetic Carrier Screening; Homovan | 1996 |
A dopaminergic neurotoxin, (R)-N-methylsalsolinol, increases in Parkinsonian cerebrospinal fluid.
Topics: Aged; Animals; Brain; Chromatography, High Pressure Liquid; Dopamine; Female; Homovanillic Acid; Hum | 1996 |
Somatostatin-like immunoreactivity, its molecular forms and monoaminergic metabolites in aged and demented patients with Parkinson's disease--effect of L-Dopa.
Topics: Aged; Aged, 80 and over; Aging; Biogenic Monoamines; Dementia; Female; Homovanillic Acid; Humans; Hy | 1996 |
Alzheimer's disease and its Lewy body variant: a clinical analysis of postmortem verified cases.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Basal Ganglia Diseases; Body Height; Delusions; Diagn | 1996 |
Dopaminergic responses to striatal damage.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Brain Tissue Transplantation; Corpus Striatum; Dihyd | 1996 |
Plasma HVA and MHPG in psychiatric patients with renal failure and levodopa-treated Parkinson's disease.
Topics: Adult; Aged; Depressive Disorder; Female; Homovanillic Acid; Humans; Kidney Failure, Chronic; Levodo | 1996 |
Microdialysis-HPLC for plasma levodopa and metabolites monitoring in parkinsonian patients.
Topics: Aged; Carbidopa; Chromatography, High Pressure Liquid; Homovanillic Acid; Humans; Kinetics; Levodopa | 1997 |
Concentrations of indoleamine metabolic intermediates in the ventricular cerebrospinal fluid of advanced Parkinson's patients with severe postural instability and gait disorders.
Topics: 5-Hydroxytryptophan; Aged; Biogenic Amines; Cerebral Ventricles; Gait; Homovanillic Acid; Humans; Hy | 1997 |
Central levodopa metabolism in Parkinson's disease after administration of stable isotope-labeled levodopa.
Topics: Adult; Aged; Homovanillic Acid; Humans; Levodopa; Middle Aged; Parkinson Disease | 1997 |
Role of aromatic L-amino acid decarboxylase for dopamine replacement by genetically modified fibroblasts in a rat model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Aromatic-L-Amino-Acid Decarboxylases; Catecholamines; Cell | 1997 |
Thalidomide reduces MPTP-induced decrease in striatal dopamine levels in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Anti-Inflamma | 1997 |
Decreased beta-phenylethylamine in CSF in Parkinson's disease.
Topics: Aged; Chromatography, Gas; Female; Homovanillic Acid; Humans; Levodopa; Male; Mass Spectrometry; Mid | 1997 |
Cerebrospinal fluid homovanillic acid levels in rapid-onset dystonia-parkinsonism.
Topics: Adult; Aged; Antiparkinson Agents; Biomarkers; Deglutition Disorders; Dopamine; Dysarthria; Dystonia | 1998 |
Cerebrospinal fluid homovanillic acid levels are not reduced in early corticobasal degeneration.
Topics: Aged; Aged, 80 and over; Basal Ganglia; Cerebral Cortex; Homovanillic Acid; Humans; Nerve Degenerati | 1998 |
Single and repeated electroconvulsive shocks activate dopaminergic and 5-hydroxytryptaminergic neurotransmission in the frontal cortex of rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Depressive Disorder; Dopamine; Electric Stimulation; Electr | 1998 |
Salsolinol, catecholamine metabolites, and visual hallucinations in L-dopa treated patients with Parkinson's disease.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Biomarkers; Catecholamines; Female; Hallucinations | 1996 |
Elevated 5-S-cysteinyldopamine/homovanillic acid ratio and reduced homovanillic acid in cerebrospinal fluid: possible markers for and potential insights into the pathoetiology of Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Biomarkers; Chromatography, High Pressure Liquid; Dopamine; Female; Homo | 1996 |
In vivo comparison of the effects of inhibition of MAO-A versus MAO-B on striatal L-DOPA and dopamine metabolism.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Clorgyline; Corpus Striatum; Dopamine; Homovanillic Acid; L | 1995 |
ECT in Parkinson's disease. Changes in motor symptoms, monoamine metabolites and neuropeptides.
Topics: Aged; Aged, 80 and over; Biogenic Monoamines; Electroconvulsive Therapy; Female; Homovanillic Acid; | 1995 |
Hereditary form of parkinsonism--dementia.
Topics: Adult; Antiparkinson Agents; Choline O-Acetyltransferase; Dementia; Dopamine; Family Health; Female; | 1998 |
Effect of trihexyphenidyl, a non-selective antimuscarinic drug, on decarboxylation of L-dopa in hemi-Parkinson rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Biotransformation; Corpus Striatum; D | 1998 |
Rapid-onset dystonia-parkinsonism: a report of clinical, biochemical, and genetic studies in two families.
Topics: Adolescent; Adult; Age of Onset; Diagnosis, Differential; Disease Progression; Dystonia; Family Heal | 1998 |
PET imaging of the pre-synaptic dopamine uptake sites in rapid-onset dystonia-parkinsonism (RDP).
Topics: Adult; Aged; Brain Mapping; Carbon Radioisotopes; Cocaine; Corpus Striatum; Diagnosis, Differential; | 1999 |
Susceptibility to neuroleptic malignant syndrome in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Disease Susceptibility; Female; Homovanillic Acid; Humans; Hydroxyindoleace | 1999 |
Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Autoradiography; Corpus Striatum; Dementia; Dopamine; Fe | 1999 |
In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease.
Topics: Aged; Carbon Radioisotopes; Carrier Proteins; Corpus Striatum; Dopamine; Dopamine Plasma Membrane Tr | 2000 |
Serotonergic decompensation in the akinetic expression of Parkinson's disease.
Topics: Brain; Chromatography, High Pressure Liquid; Dopamine; Dyskinesia, Drug-Induced; Homovanillic Acid; | 2000 |
Manganese increases L-DOPA auto-oxidation in the striatum of the freely moving rat: potential implications to L-DOPA long-term therapy of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcysteine; Animals; Ascorbic Acid; Chlorides; Chromatography, H | 2000 |
Bromocriptine markedly suppresses levodopa-induced abnormal increase of dopamine turnover in the parkinsonian striatum.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Bromocriptine; Corpus Striatum; Dopamine; Homovanillic Acid | 2000 |
N-methyl(R)salsolinol and a neutral N-methyltransferase as pathogenic factors in Parkinson's disease.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Brain; Female; Homovanillic Acid; Humans; Levodopa | 2000 |
Antidopaminergic effects of 1,2,3,4-tetrahydroisoquinoline and salsolinol.
Topics: Animals; Antiparkinson Agents; Apomorphine; Binding, Competitive; Brain Chemistry; Catalepsy; Dopami | 2000 |
The influence of pallidal deep brain stimulation on striatal dopaminergic metabolism in the rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Denervation; Dopamine; Electric Stimulation Therapy; Globus | 2000 |
Sensitivity to MPTP is not increased in Parkinson's disease-associated mutant alpha-synuclein transgenic mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Amino | 2001 |
Forced limb-use effects on the behavioral and neurochemical effects of 6-hydroxydopamine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Behavior, Animal; Body Temperature; Casts, Sur | 2001 |
Biochemical alterations during medication withdrawal in Parkinson's disease with and without neuroleptic malignant-like syndrome.
Topics: Aged; Analysis of Variance; Female; Homovanillic Acid; Humans; Male; Neuroleptic Malignant Syndrome; | 2001 |
Biochemical and pathological study of endogenous 1-benzyl-1,2,3,4-tetrahydroisoquinoline-induced parkinsonism in the mouse.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Dopamine; Dru | 2001 |
Role of nitric oxide in a progressive neurodegeneration model of Parkinson's disease in the rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Corpus Striatum; Disease Models, Animal; | 2001 |
COMT-inhibition increases serum levels of dihydroxyphenylacetic acid (DOPAC) in patients with advanced Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Aged, 80 and over; Antiparkinson Agents; Benzophenones; Catech | 2002 |
Glutathione depletion in nigrostriatal slice cultures: GABA loss, dopamine resistance and protection by the tetrahydrobiopterin precursor sepiapterin.
Topics: Animals; Animals, Newborn; Biopterins; Buthionine Sulfoximine; Coculture Techniques; Dopamine; Enzym | 2002 |
The neurochemistry of Parkinson's disease: effect of L-dopa therapy.
Topics: Aged; Brain; Catechol O-Methyltransferase; Dihydroxyphenylalanine; Dopa Decarboxylase; Dopamine; Fem | 1975 |
Familial fatal Parkinsonism with alveolar hypoventilation and mental depression.
Topics: Brain; Brain Chemistry; Depression; Dopa Decarboxylase; Dopamine; gamma-Aminobutyric Acid; Glutamate | 1979 |
Intravenous probenecid loading. Effects on plasma and cerebrospinal fluid probenecid levels and on monoamine metabolites in cerebrospinal fluid.
Topics: Administration, Oral; Adult; Dose-Response Relationship, Drug; Female; Homovanillic Acid; Humans; Hu | 1976 |
Metabolic studies with bromocriptine in patients with idiopathic parkinsonism and Huntington's chorea.
Topics: Bromocriptine; Ergolines; Growth Hormone; Homovanillic Acid; Humans; Huntington Disease; Hydroxyindo | 1976 |
Recent advances in the biochemical pharmacology of extrapyramidal movement disorders.
Topics: Animals; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Homovanillic Acid; Humans; Huntington | 1977 |
Effect of metoclopramide on turnover of brain dopamine noradrenaline and 5-hydroxytryptamine.
Topics: Animals; Brain; Brain Chemistry; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Homova | 1975 |
[Parkinson's disease: neuro-anatomical, biochemical and pharmicotherapeutic aspects].
Topics: Basal Ganglia; Dopamine; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Levodopa; Middle Aged; | 1975 |
Hydroxylase cofactor activity in cerebrospinal fluid of normal subjects and patients with Parkinson's disease.
Topics: Biopterins; Homovanillic Acid; Humans; Methods; Parkinson Disease; Pteridines | 1979 |
[Cerebrospinal fluid homovanillic acid in paralysis agitans and spinocerebellar degeneration (author's transl)].
Topics: Cerebellar Diseases; Homovanillic Acid; Humans; Parkinson Disease; Phenylacetates; Spinal Cord Disea | 1979 |
Assay of 4-hydroxy-3-methoxyphenylacetic (homovanillic) acid by liquid chromatography with electrochemical detection.
Topics: Adult; Chromatography, Liquid; Electrochemistry; Homovanillic Acid; Humans; Neuroblastoma; Parkinson | 1979 |
Ventricular fluid homovanillic acid and 5-hydroxyindoleacetic acid concentrations in patients with movement disorders.
Topics: Adult; Aged; Cerebral Palsy; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Levodopa; Middle A | 1978 |
Progressive dystonia with marked diurnal fluctuation.
Topics: Child; Circadian Rhythm; Diagnosis, Differential; Dystonia; Female; Homovanillic Acid; Humans; Hydro | 1978 |
CSF studies on the relationship between dopamine and 5-hydroxytryptamine in Parkinsonism and other movement disorders.
Topics: Aged; Athetosis; Carbidopa; Chorea; Dihydroxyphenylalanine; Dopamine; Dystonia Musculorum Deformans; | 1977 |
Paradoxial response to dopaminergic agents in parkinsonism.
Topics: Acetonitriles; Aged; Carbidopa; Ergolines; Homovanillic Acid; Humans; Hydrazines; Levodopa; Male; Pa | 1978 |
Studies on urinary DOPAC in man by means of a sensitive automated procedure.
Topics: 3,4-Dihydroxyphenylacetic Acid; Addison Disease; Adrenal Gland Neoplasms; Adult; Aged; Autoanalysis; | 1978 |
Receptor basis for dopaminergic supersensitivity in Parkinson's disease.
Topics: Adult; Aged; Apomorphine; Caudate Nucleus; Dopamine; Haloperidol; Homovanillic Acid; Humans; Levodop | 1978 |
Neurochemistry of Parkinson's disease: relation between striatal and limbic dopamine.
Topics: Affective Symptoms; Caudate Nucleus; Corpus Striatum; Dopamine; Homovanillic Acid; Humans; Limbic Sy | 1978 |
Brain dopamine receptor stimulation and the relief of Parkinsonism: relationship between bromocriptine and levodopa.
Topics: Benserazide; Brain; Bromocriptine; Female; Homovanillic Acid; Humans; Levodopa; Male; Middle Aged; P | 1978 |
Juvenile parkinsonism: a patient with possible primary striatal dysfunction.
Topics: Adolescent; Corpus Striatum; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Male; Parkinson Di | 1978 |
L-deprenyl treatment of on-off phenomena in Parkinson's disease.
Topics: Aged; Benserazide; Dopamine; Drug Therapy, Combination; Female; Homovanillic Acid; Humans; Hydroxyin | 1978 |
The simultaneous determination by selected ion monitoring of the levels of homovanillic, isohomovanillic, 3,4-dihydroxyphenylacetic and 3-methoxy-4-hydroxymandelic acids in single biological samples.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Chemistry; Cats; Chromatography, Gas; Dihydroxyphenyl | 1975 |
Juvenile parkinsonism treated with levodopa.
Topics: Age Factors; Child; Child, Preschool; Drug Evaluation; Female; Homovanillic Acid; Humans; Hydroxyind | 1977 |
[Abnormal movements of patients with Parkinsonism treated with L-dopa and anomalies of dopamine metabolism].
Topics: Dopamine; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Homovanillic Acid; Hum | 1977 |
Correlation of clinical symptoms, HVA and 5-HIAA in csf and plasma L-DOPA in Parkinsonian patients treated with L-DOPA and L-DOPA + RO 4-4602.
Topics: Benserazide; Drug Therapy, Combination; Female; Homovanillic Acid; Humans; Hydrazines; Hydroxyindole | 1977 |
Urinary monoamine metabolite excretion in disorders of movement. Effects of amantadine and levodopa.
Topics: Amantadine; Chorea; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Levodopa; Methylhistamines; | 1977 |
Dopamine in thelimbic regions of the human brain: normal and abnormal.
Topics: Adult; Aged; Brain Chemistry; Dopamine; Female; Homovanillic Acid; Humans; Limbic System; Male; Midd | 1977 |
Brain dopamine turnover and the relief of parkinsonism.
Topics: Brain; Bromocriptine; Dopamine; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Parkinson Disea | 1977 |
The Parkinsonian syndrome and its dopamine correlates.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Aged; Dopamine; Extrapyramidal Tracts; Female; Homovanillic A | 1977 |
Brain dopamine turnover and the relief of parkinsonism.
Topics: Aromatic Amino Acid Decarboxylase Inhibitors; Bromocriptine; Homovanillic Acid; Humans; Hydroxyindol | 1977 |
CNS compensation to dopamine neuron loss in Parkinson's disease.
Topics: Acetylcholine; Aminobutyrates; Brain; Choline O-Acetyltransferase; Corpus Striatum; Dopa Decarboxyla | 1977 |
Hereditary Parkinsonism-dystonia with sustained control by L-DOPA and anticholinergic medication.
Topics: Adolescent; Adult; Aged; Dopamine beta-Hydroxylase; Dystonia Musculorum Deformans; Female; Growth Ho | 1976 |
Autosomal dominant striatonigral degeneration. A clinical, pathologic, and biochemical study of a new genetic disorder.
Topics: Adult; Aged; Brain Diseases; Caudate Nucleus; Cerebellar Nuclei; Corpus Striatum; Eye Movements; Fem | 1976 |
[Striato-nigral degeneration. A propos of 2 anatomo-clinical cases].
Topics: Brain Diseases; Corpus Striatum; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Male; | 1976 |
14C-homovanillic acid in the cerebrospinal fluid of parkinsonian patients after intravenous 14C-L-dopa.
Topics: Aged; Brain; Carbidopa; Carboxy-Lyases; Dopamine; Female; Homovanillic Acid; Humans; Levodopa; Male; | 1976 |
Dopamine correlates of neurological and psychological status in untreated Parkinsonism.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Affect; Aged; Dopamine; Female; Homovanillic Acid; Humans; Le | 1976 |
Sequential parkinsonism and chorea following "mild" inluenza.
Topics: Adolescent; Antibodies, Viral; Chorea; Homovanillic Acid; Humans; Influenza A virus; Influenza, Huma | 1976 |
Dopaminergic mechanisms in patients with extrapyramidal disease.
Topics: Animals; Biogenic Amines; Brain; Caffeine; Clonidine; Dopamine; Drug Evaluation; Drug Therapy, Combi | 1975 |
Effects of levodopa on the bladder outlet.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Dopamine; Female; Homovanillic Acid; Humans; Levodopa; Male; M | 1975 |
Assessment of cerebrospinal fluid levels of dopamine metabolites by gas chromatography.
Topics: 3,4-Dihydroxyphenylacetic Acid; Chromatography, Gas; Dopamine; Homovanillic Acid; Levodopa; Parkinso | 1975 |
Dopamine metabolism in depressions, psychoses, and Parkinson's disease: the problem of the specificity of biological variables in behaviour disorders.
Topics: Adjustment Disorders; Bipolar Disorder; Brain; Carboxy-Lyases; Depression; Dihydroxyphenylalanine; D | 1975 |
Urinary excretion of monoamines and their metabolites in patients with Parkinson's disease. Response to long-term treatment with levodopa alone or in combination with a dopa decarboxylase inhibitor and clinical correlations.
Topics: 3,4-Dihydroxyphenylacetic Acid; Benserazide; Biogenic Amines; Dopamine; Female; Homovanillic Acid; H | 1975 |
Caudate nucleus pathology in Parkinson's disease: ultrastructural and biochemical findings in biopsy material.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Astrocytoma; Biopsy; Catecholamines; Caudate Nucleus; Child; | 1992 |
Parkinson's disease and dementia: clinical and neurochemical correlations.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic A | 1992 |
Markers of dopamine metabolism in Parkinson's disease. The Parkinson Study Group.
Topics: Aged; Biomarkers; Chromatography, Gas; Chromatography, High Pressure Liquid; Dopamine; Female; Homov | 1992 |
Lack of changes in ventricular cerebrospinal fluid concentrations of homovanillic acid following acute challenge with levodopa.
Topics: Aged; Carbidopa; Cerebral Ventricles; Drug Combinations; Female; Homovanillic Acid; Humans; Hydrocep | 1992 |
Opioid peptides in Parkinson's disease: effects of dopamine repletion.
Topics: Adult; Aged; Aged, 80 and over; Dopamine; Dynorphins; Endorphins; Enkephalin, Methionine; Female; Ho | 1991 |
Somatostatin-like immunoreactivity in the cerebrospinal fluid of aged patients with Parkinson's disease. The effect of dopatherapy.
Topics: Aged; Aged, 80 and over; Benserazide; Bromocriptine; Cognition Disorders; Female; Homovanillic Acid; | 1990 |
Intracarotid 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration: biochemical and behavioral observations in a primate model of hemiparkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Brain; Carotid Arteries; Do | 1990 |
Monoamine metabolites and neuropeptides in patients with Parkinson's disease, Huntington's chorea, Shy-Drager syndrome, and torsion dystonia.
Topics: Dystonia Musculorum Deformans; Enkephalin, Methionine; Homovanillic Acid; Humans; Huntington Disease | 1990 |
The effect of R-(-)-deprenyl in de novo parkinsonian patients pretreated with levodopa and decarboxylase inhibitor correlated to depression and MHPS, HIAA, and HVA levels of cerebrospinal fluid.
Topics: Carboxy-Lyases; Depressive Disorder; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Le | 1990 |
Behavioral recovery from MPTP-induced parkinsonism in monkeys after intracerebral tissue implants is not related to CSF concentrations of dopamine metabolites.
Topics: Adrenal Medulla; Amnion; Animals; Brain Tissue Transplantation; Caudate Nucleus; Disease Models, Ani | 1990 |
The threshold of pain and neurotransmitter's change on pain in Parkinson's disease.
Topics: Aged; beta-Endorphin; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Male; Methoxyhydr | 1990 |
Neurochemical and behavioural features induced by chronic low dose treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset: implications for Parkinson's disease?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Biogenic Amin | 1991 |
Biogenic amines and metabolites in spinal cord of patients with Parkinson's disease and amyotrophic lateral sclerosis.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Aged, 80 and over; Amyotrophic Lateral Sclerosis; Autopsy; Bio | 1991 |
Topography, extent, and clinical relevance of neurochemical deficits in dementia of Lewy body type, Parkinson's disease, and Alzheimer's disease.
Topics: Adult; Aged; Alzheimer Disease; Cerebral Cortex; Choline O-Acetyltransferase; Dementia; Hallucinatio | 1991 |
Aging produces a specific pattern of striatal dopamine loss: implications for the etiology of idiopathic Parkinson's disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aging; Analysis of Variance; Corpus Striatum; Dopamine; | 1992 |
A study of brain dopamine sulfate levels in relation to free dopamine and homovanillic acid in Parkinson's disease.
Topics: Brain; Cadaver; Dopamine; Homovanillic Acid; Humans; Osmolar Concentration; Parkinson Disease; Tissu | 1991 |
Temporal relationships between plasma and cerebrospinal fluid pharmacokinetics of levodopa and clinical effect in Parkinson's disease.
Topics: Aged; Carbidopa; Dopamine; Female; Homovanillic Acid; Humans; Levodopa; Male; Middle Aged; Parkinson | 1991 |
Hypokinesia, rigidity, and tremor induced by hypothalamic 6-OHDA lesions in the rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Dopamine; Dyskinesia, Drug-Induced; Homovanillic Aci | 1991 |
Levels of pros-methylimidazoleacetic acid: correlation with severity of Parkinson's disease in CSF of patients and with the depletion of striatal dopamine and its metabolites in MPTP-treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Aged; Animals; Cerebra | 1991 |
Long-term effect of MPTP in the mouse brain in relation to aging: neurochemical and immunocytochemical analysis.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Aging; Animals; Brain; | 1990 |
Decreased dopamine in the retinas of patients with Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Aged, 80 and over; Dopamine; Female; Homovanillic Acid; Humans | 1990 |
GM1 gangliosides alter acute MPTP-induced behavioral and neurochemical toxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Ani | 1990 |
Neuropsychological profile linked to low dopamine: in Alzheimer's disease, major depression, and Parkinson's disease.
Topics: Aged; Alzheimer Disease; Attention; Depressive Disorder; Dopamine; Homovanillic Acid; Humans; Male; | 1990 |
Adrenal medullary transplantation into the brain for treatment of Parkinson's disease: clinical outcome and neurochemical studies.
Topics: Activities of Daily Living; Adrenal Medulla; Adult; Caudate Nucleus; Cells, Cultured; Dopamine; Epin | 1990 |
MAO and L-dopa treatment of Parkinson's disease.
Topics: Aged; Carbidopa; Dopamine; Drug Combinations; Female; Homovanillic Acid; Humans; Levodopa; Male; Mid | 1990 |
Corticoliberin, somatocrinin and amine contents in normal and parkinsonian human hypothalamus.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Biogenic Amines; Corticotropin-Releasing Hormone; Dopamine; Fe | 1985 |
[Neurotransmitters and degenerative diseases in the central nervous system].
Topics: Acetylcholinesterase; Aged; Aging; Brain Diseases; Dementia; Dopamine; Homovanillic Acid; Humans; Hy | 1986 |
Clinical and biochemical features of depression in Parkinson's disease.
Topics: Aged; Depressive Disorder; Dexamethasone; Growth Hormone; Homovanillic Acid; Humans; Hydroxyindoleac | 1986 |
Degeneration of noradrenergic and serotonergic but not dopaminergic neurones in the lumbar spinal cord of parkinsonian patients.
Topics: Aged; Dopamine; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Male; Nerve Degeneratio | 1986 |
Somatostatin-like immunoreactivity in the cerebrospinal fluid of patients with Parkinson's disease and its relation to dementia.
Topics: Acetylcholinesterase; Adult; Aged; Aged, 80 and over; Dementia; Female; Homovanillic Acid; Humans; M | 1986 |
Depression and Parkinson's disease.
Topics: Depressive Disorder; Dexamethasone; Growth Hormone; Homovanillic Acid; Humans; Hydrocortisone; Hydro | 1987 |
Clinical and biochemical correlates of bradyphrenia in Parkinson's disease.
Topics: Aged; Alzheimer Disease; Arousal; Attention; Biogenic Amines; Cognition Disorders; Homovanillic Acid | 1987 |
Diminished levels of ventricular fluid norepinephrine metabolite and somatostatin in childhood-onset dystonia.
Topics: Adolescent; Adult; Age Factors; Cerebral Palsy; Child; Child, Preschool; Dystonia; Homovanillic Acid | 1988 |
Unresponsiveness to L-DOPA in parkinsonian patients: a study of homovanillic acid concentration in the cerebrospinal fluid.
Topics: Aged; Biomarkers; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Levodopa; Male; Metho | 1989 |
Clinical, biochemical, and neuropathologic findings following transplantation of adrenal medulla to the caudate nucleus for treatment of Parkinson's disease.
Topics: Activities of Daily Living; Adrenal Medulla; Caudate Nucleus; Follow-Up Studies; Homovanillic Acid; | 1989 |
Critical approach to intrastriatal medullary adrenal implants via open surgery in parkinsonism. Case report.
Topics: Adrenal Medulla; Aged; Caudate Nucleus; Graft Survival; Homovanillic Acid; Humans; Hydroxyindoleacet | 1989 |
The effect of R-(-)-deprenyl in de novo parkinsonian patients pretreated with levodopa and decarboxylase inhibitor correlated to depression and MHPG, HIAA and HVA levels in the cerebrospinal fluid.
Topics: Benserazide; Depression; Double-Blind Method; Drug Therapy, Combination; Female; Glycols; Homovanill | 1989 |
CSF monamine metabolites in movement disorders and normal aging.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Aged; Dyskinesia, Drug-Induced; Dystonia; Female; Glycols; Ho | 1985 |
The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Corpus Striatum; Dopamine; Female; Homovanillic | 1985 |
CSF monoamine metabolite levels in Alzheimer's and Parkinson's disease.
Topics: Adult; Aged; Alzheimer Disease; Female; Glycols; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid | 1985 |
Beta-carboline analogues of N-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP): endogenous factors underlying idiopathic parkinsonism?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Aotus trivirg | 1985 |
The coenzyme nicotinamide adenine dinucleotide (NADH) improves the disability of parkinsonian patients.
Topics: Aged; Aged, 80 and over; Homovanillic Acid; Humans; Injections, Intravenous; Middle Aged; Movement D | 1989 |
Magnitude of response to levodopa in Parkinson disease as it relates to peripheral and central measurements of levodopa and associated metabolites.
Topics: Aged; Carbidopa; Drug Combinations; Homovanillic Acid; Humans; Levodopa; Male; Methyldopa; Middle Ag | 1989 |
[Clinical significance of homovanillic acid analysis in endocrine tests of the adrenal medulla and sympathetic nervous system].
Topics: Adrenal Medulla; Alzheimer Disease; Chromatography, High Pressure Liquid; Homovanillic Acid; Humans; | 1989 |
Catecholamines in CSF, plasma, and tissue after autologous transplantation of adrenal medulla to the brain in patients with Parkinson's disease.
Topics: Adrenal Medulla; Adult; Catecholamines; Caudate Nucleus; Dopamine; Epinephrine; Homovanillic Acid; H | 1989 |
[The concentration of homovanillic acid and leucine-enkephalin in the lumbar CSF of patients with Parkinson's disease before and after madopar treatment].
Topics: Adult; Aged; Benserazide; Carboxy-Lyases; Drug Combinations; Enkephalin, Leucine; Female; Homovanill | 1989 |
CSF cyclic nucleotides and somatostatin in Parkinson's disease.
Topics: Acetylcholinesterase; Aged; Cyclic AMP; Cyclic GMP; Homovanillic Acid; Humans; Male; Middle Aged; Pa | 1986 |
Reversal of parkinsonism by fetal nerve cell transplants in primate brain.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Chlorocebus aethiops; Corpus Striatum; Fetus; | 1987 |
Biochemical analysis of caudate nucleus biopsy samples from parkinsonian patients.
Topics: Adult; Biopsy; Caudate Nucleus; Dopamine; Female; Homovanillic Acid; Humans; Male; Middle Aged; Park | 1988 |
Cerebrospinal fluid homovanillic acid and parkinsonism in Huntington's disease.
Topics: Adult; Homovanillic Acid; Humans; Huntington Disease; Middle Aged; Movement Disorders; Parkinson Dis | 1988 |
Cerebrospinal fluid levels of angiotensin-converting enzyme, acetylcholinesterase, and dopamine metabolites in dementia associated with Alzheimer's disease and Parkinson's disease: a correlative study.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcholinesterase; Aged; Alzheimer Disease; Cerebrospinal Fluid P | 1986 |
High-performance liquid chromatographic method for measuring homovanillic acid in cerebrospinal fluid using electrochemical detection with internal standardization.
Topics: Chromatography, High Pressure Liquid; Electrochemistry; Homovanillic Acid; Humans; Indicators and Re | 1988 |
Evaluation of the biological activity of several analogs of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Corpus | 1987 |
Behavioral and biochemical effects of nicotine in an MPTP-induced mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat | 1987 |
[Clinical and biochemical aspects of early-onset Parkinson's disease].
Topics: Adult; Child; Female; Homovanillic Acid; Humans; Male; Parkinson Disease; Retrospective Studies | 1986 |
Parkinson's disease and dementia: norepinephrine and dopamine in locus ceruleus.
Topics: Aged; Aged, 80 and over; Brain; Dementia; Desipramine; Dopamine; Homovanillic Acid; Humans; Locus Co | 1987 |
Predictive factors for cognitive deterioration and dementia in Parkinson's disease.
Topics: Cognition Disorders; Dementia; Electroencephalography; Homovanillic Acid; Humans; Levodopa; Parkinso | 1987 |
Biochemical effects of chronic L-dopa treatment in rats: implications for emergence of tolerance phenomena in patients with Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Administration, Oral; Animals; Brain; Dopamine; Drug Administration | 1987 |
Laterality and neurochemical findings in Parkinson's disease.
Topics: Brain Chemistry; Functional Laterality; Homovanillic Acid; Humans; Parkinson Disease | 1986 |
CSF Met-enkephalin levels in Parkinson's disease.
Topics: Age Factors; Enkephalin, Methionine; Homovanillic Acid; Humans; Parkinson Disease; Research Design | 1985 |
Carbidopa dosage modifies L-dopa induced side effects and blood levels of L-dopa and other amino acids in advanced parkinsonism.
Topics: Aged; Carbidopa; Drug Therapy, Combination; Female; Homovanillic Acid; Humans; Kinetics; Levodopa; M | 1985 |
Clinical significance of probenecid test.
Topics: Brain Diseases; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Parkinson Disease; Phenylacetat | 1973 |
Variation of levodopa metabolism with gastrointestinal absorption site.
Topics: Administration, Oral; Aged; Animals; Biotransformation; Catechols; Dihydroxyphenylalanine; Dogs; Duo | 1974 |
Probenecid test in Parkinson's disease.
Topics: Homovanillic Acid; Humans; Methods; Parkinson Disease; Probenecid | 1971 |
Use of cerebrospinal fluid drawn at pneumoencephalography in the study of monoamine metabolism in man.
Topics: Adolescent; Adult; Brain Diseases; Epilepsy, Temporal Lobe; Epilepsy, Tonic-Clonic; Female; Homovani | 1974 |
Norepinephrine metabolism in the central nervous system of man: studies using 3-methoxy-4-hydroxyphenylethylene glycol levels in cerebrospinal fluid.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Carbon Radioisotopes; Cerebrospinal Fluid; Child; | 1973 |
Central monoamine metabolism in man. Effect of putative dopamine receptor agonists and antagonists.
Topics: Adult; Basal Ganglia Diseases; Brain; Central Nervous System Diseases; Dopamine; Haloperidol; Homova | 1973 |
Involuntary movements other than Parkinsonism: biochemical aspects.
Topics: Acute Disease; Animals; Athetosis; Basal Ganglia; Brain; Dopamine; Fecal Incontinence; Homovanillic | 1973 |
Adenosine 3',5'-monophosphate in cerebrospinal fluid. Effect of drugs and neurologic disease.
Topics: Adolescent; Adult; Aged; Cerebellar Diseases; Child; Cyclic AMP; Dihydroxyphenylalanine; Female; Hom | 1973 |
Occurrence of Parkinson's disease in black patients at Charity Hospital in New Orleans.
Topics: Adult; Age Factors; Aged; Arylsulfonates; Black People; Brain; Female; Homovanillic Acid; Humans; Lo | 1974 |
Dopaminergic nervous transmission in Parkinson's disease.
Topics: Acetylcholinesterase; Aromatic Amino Acid Decarboxylase Inhibitors; Autopsy; Brain; Brain Chemistry; | 1974 |
Proceedings: Clinical studies of dopaminergic mechanisms.
Topics: Antiparkinson Agents; Dihydroxyphenylalanine; Dioxoles; Dopamine; Haloperidol; Homovanillic Acid; Hu | 1974 |
Clinical studies of dopaminergic mechanisms.
Topics: Antiparkinson Agents; Dioxoles; Dopamine; Drug Evaluation; Haloperidol; Homovanillic Acid; Humans; L | 1974 |
Dopa, 3-O-methyldopa, and metabolites in urine during oral L-3-O-methyldopa therapy.
Topics: Administration, Oral; Autoanalysis; Catecholamines; Dealkylation; Decarboxylation; Dihydroxyphenylal | 1974 |
Cerebrospinal homovanillic acid and parkinsonism.
Topics: Age Factors; Dihydroxyphenylalanine; Fluorometry; Homovanillic Acid; Humans; Parkinson Disease; Phen | 1974 |
Parkinson's disease and amine metabolites in cerebrospinal fluid: implications for L-Dopa therapy.
Topics: Aged; Aromatic Amino Acid Decarboxylase Inhibitors; Depression, Chemical; Dopa Decarboxylase; Drug C | 1974 |
Plasma dopa concentrations and the "on-off" effect after chronic treatment of Parkinson's disease.
Topics: Dietary Proteins; Dihydroxyphenylalanine; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Levod | 1974 |
The ventricular fluid pressure and the concentration of homovanillic acid in different parts of the cerebrospinal fluid system in patients with Parkinson's disease.
Topics: Aged; Cerebral Ventricles; Dopamine; Female; Homovanillic Acid; Humans; Intracranial Pressure; Male; | 1972 |
Sulphate conjugation and L-dopa treatment of Parkinsonian patients.
Topics: Aged; Dihydroxyphenylalanine; Dopamine; Dose-Response Relationship, Drug; Female; Homovanillic Acid; | 1973 |
Biochemical investigations in Parkinsonism. A study of the metabolites of the biogenic amines in the lumbar CSF.
Topics: Dihydroxyphenylalanine; Dopamine; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Microscopy, F | 1972 |
[Study of dopamine and noradrenaline in the brains of three patients with Parkinson's disease who died in the course of treatment with L-dopa].
Topics: Autopsy; Brain Chemistry; Dihydroxyphenylalanine; Dopamine; Homovanillic Acid; Humans; Norepinephrin | 1972 |
[Pharmacological approach to the prognosis of biochemical changes and response to treatment in the therapy of Parkinsonian syndromes].
Topics: Acetylcholine; Dihydroxyphenylalanine; Dopamine; Homovanillic Acid; Humans; Parkinson Disease; Progn | 1972 |
Proceedings: Effect of amantadine on the urinary excretion of some monoamines and metabolites in normal and parkinsonian subjects.
Topics: Amantadine; Amines; Dihydroxyphenylalanine; Dopamine; Epinephrine; Histamine; Homovanillic Acid; Hum | 1972 |
Acid monoamine metabolites in the cerebrospinal fluid of Parkinsonian patients treated with levodopa alone or combined with a decarboxylase inhibitor.
Topics: Adult; Aged; Carboxy-Lyases; Dihydroxyphenylalanine; Dopamine; Dose-Response Relationship, Drug; Dru | 1973 |
Interactions of L-dopa and amantadine in patients with Parkinsonism.
Topics: Amantadine; Dihydroxyphenylalanine; Drug Interactions; Evaluation Studies as Topic; Female; Homovani | 1973 |
An analysis of six patients with Parkinson's disease who have been unresponsive to L-dopa therapy.
Topics: Aged; Carbidopa; Diagnosis, Differential; Dihydroxyphenylalanine; Evaluation Studies as Topic; Femal | 1973 |
Amine metabolites in the cerebrospinal fluid in Parkinson's disease and the response to levodopa.
Topics: Adult; Aged; Dihydroxyphenylalanine; Dopamine; Dose-Response Relationship, Drug; Electroencephalogra | 1973 |
Striatonigral degeneration. Response to levodopa therapy with pathological and neurochemical correlation.
Topics: Basal Ganglia; Carboxy-Lyases; Cerebellum; Cerebral Cortex; Corpus Striatum; Diencephalon; Dihydroxy | 1973 |
Monitoring phenylalanine-tyrosine metabolism by high-resolution liquid chromatography of urine.
Topics: Aromatic Amino Acid Decarboxylase Inhibitors; Autistic Disorder; Carbidopa; Catechols; Child; Chroma | 1973 |
Decreased dopamine and homovanillic acid excretion in a case with chlorpromazine-induced Parkinsonism.
Topics: Chlorpromazine; Dopamine; Homovanillic Acid; Humans; Male; Parkinson Disease; Parkinson Disease, Sec | 1973 |
Separation and determination of urinary homovanillic acid and iso-homovanillic acid by gas-liquid chromatography and electron capture detection.
Topics: Adolescent; Adult; Child; Chromatography, Gas; Creatine; Dihydroxyphenylalanine; Homovanillic Acid; | 1973 |
Failure of cerebrospinal fluid homovanillic acid to predict levodopa response in Parkinson's disease.
Topics: Dihydroxyphenylalanine; Disability Evaluation; Evaluation Studies as Topic; Homovanillic Acid; Human | 1973 |
Iso-homovanillic acid determination in cerebrospinal fluid and in urine during L-DOPA treatment of Parkinson's disease.
Topics: Aromatic Amino Acid Decarboxylase Inhibitors; Chromatography, Thin Layer; Dihydroxyphenylalanine; Ho | 1973 |
Metabolic interactions of pyridoxine, levodopa, and carbidopa in Parkinson's disease.
Topics: Brain; Carbidopa; Dihydroxyphenylalanine; Dopa Decarboxylase; Dopamine; Homovanillic Acid; Humans; H | 1973 |
Responses of the urinary excretion of homovanillic acid and of 5-hydroxy-indol-acetic acid to treatment with L-dopa and amantadine.
Topics: Amantadine; Dihydroxyphenylalanine; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Parkinson D | 1973 |
[Determination of homovanillic acid in the cerebrospinal fluid of Parkinson's disease patients and control group].
Topics: Dihydroxyphenylalanine; Female; Homovanillic Acid; Humans; Male; Parkinson Disease; Phenylacetates | 1973 |
[Abnormal movements induced by L-Dopa and dopamine metabolism disorders].
Topics: Benzoates; Dihydroxyphenylalanine; Dopamine; Electrocoagulation; Female; Homovanillic Acid; Humans; | 1973 |
Parkinson's disease, cerebral arteriosclerosis, and senile dementia. Clinical features and response to levodopa.
Topics: Aged; Dementia; Dihydroxyphenylalanine; Electroencephalography; Female; Gait; Homovanillic Acid; Hum | 1974 |
Levodopa, carbidopa, and pyridoxine in Parkinson disease. Metabolic interactions.
Topics: Carbidopa; Dihydroxyphenylalanine; Dopa Decarboxylase; Dopamine; Drug Interactions; Drug Synergism; | 1974 |
Cerebrospinal fluid homovanillic acid and iso-homovanillic acid: a gas-liquid chromatographic method.
Topics: Chromatography, Gas; Dihydroxyphenylalanine; Evaluation Studies as Topic; Fluoroacetates; Homovanill | 1974 |
Cerebrospinal fluid pH and monoamine and glucolytic metabolites in Alzheimer's disease.
Topics: Affective Symptoms; Aged; Bicarbonates; Carbon Dioxide; Dementia; Female; Glycolysis; Homovanillic A | 1974 |
Viral infections in the central nervous system and 5-hydroxytryptamine metabolism.
Topics: Animals; Brain; Brain Diseases; Catecholamines; Coxsackievirus Infections; Dopamine; Encephalitis; H | 1974 |
Relationship of age and mood to monoamine metabolites in cerebrospinal fluid in parkinsonism.
Topics: Age Factors; Aged; Biogenic Amines; Depression; Dihydroxyphenylalanine; Emotions; Female; Homovanill | 1974 |
"On-off" phenomenon with levodopa therapy in Parkinsonism. Clinical and pharmacologic correlations and the effect of intramuscular pyridoxine.
Topics: Adult; Carbidopa; Dihydroxyphenylalanine; Drug Synergism; Evaluation Studies as Topic; Female; Homov | 1974 |
Fusaric acid in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Dihydroxyphenylalanine; Female; Homovanillic Acid; Humans; Hydroxyindole | 1974 |